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Abstract: The use of antiplatelet agents, specifically the thienopyridines, has become a standard 
of care in the approach to the patient presenting with an acute coronary syndrome. These drugs 
irreversibly inhibit the platelet by permanently binding to the surface P2Y12 receptor and block-
ing the downstream fibrinogen cross-linking between platelets, which leads to aggregation and 
thrombus. However, currently available therapeutic choices are limited by potential interaction 
with other medications, slow hepatic conversion to active metabolite, genetic resistance, and 
narrow therapeutic safety margin. In order to overcome these disadvantages, there has been 
an interest in developing alternatives to thienopyridines. Recent investigations have included 
ticagrelor, a reversible inhibitor of the P2Y12 platelet receptor, which appears to have overcome 
several drawbacks of the current thienopyridines. Its unique pharmacokinetic and pharmacody-
namic profiles result in an inhibition of platelet aggregation that is rapid, high, consistent, and 
less susceptible to interpatient variability than currently available P2Y12 inhibitors. In addition, 
ticagrelor offers a potential mortality advantage not apparent with current agents. Although 
questions regarding the nature, magnitude, and clinical significance of several observed adverse 
effects (dyspnea and ventricular pauses) remain unanswered, it appears that ticagrelor may 
represent a significant advancement over currently available oral antiplatelet agents.
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Introduction
Coronary heart disease (CHD) remains a significant burden in both developed and 
undeveloped countries. Worldwide, cardiovascular disease is the major cause of death, 
resulting in over 17 million deaths per year.1 Despite the proclamations by Brown and 
Goldstein2 in 1996 that coronary disease as a major public health problem could end 
early in the next century, some have voiced concern that people are starting to lose 
the battle against heart disease.3 Recent predictions of a pending “vascular tsunami 
of pandemic proportions” have appeared in the literature.4 Clearly, CHD consumes a 
significant portion of our limited health care resources.
Acute coronary syndrome (ACS) is often the initial presentation of an individual 
manifesting coronary artery disease (CAD). The majority of ACS presents as non-
ST-segment elevation myocardial infarction (NSTEMI), with the remainder as 
  ST-segment elevation myocardial infarction (STEMI), which accounts for 29%–47% 
of the ACS depending on the registry or database surveyed.5 Interestingly, it was 
recently reported that the incidence of STEMI has dramatically decreased since 
1999, from 133 cases per 100,000 person-years to 50 cases per 100,000   person-years 
in 2008.6Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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ACS typically begins with the rupture or erosion of vulner-
able plaque in a coronary artery, which results in the exposure 
of elements under the endothelial layer, such as collagen or von 
Willebrand factor, to circulating blood. These ligands trigger 
a series of responses, including platelet adhesion, activation, 
and aggregation.7 The eventual downstream effect of this pro-
cess is a coronary thrombus, which may be occlusive (more 
often associated with a STEMI) or nonocclusive resulting in 
a NSTEMI. Understanding the natural history of the culprit 
plaque has been an area of active research, and recent investiga-
tions with various imaging modalities hope to discover ways 
of identifying vulnerable plaque before it ruptures.8
Strategies used to reduce the thrombotic risk in ACS include 
antiplatelet agents (aspirin, thienopyridines, and glycoprotein 
[GP] IIb/IIIa inhibitors) and antithrombin drugs (unfraction-
ated heparin, low molecular weight heparins, direct thrombin 
inhibitors, and factor Xa inhibitors).9 Of note, the evaluation 
of oral GP IIb/IIIa inhibitors in patients with ACS was disap-
pointing when results suggested net harm with these agents.10
The utility of oral antiplatelet agents in the therapeutic 
approach to ACS has been established by previous trials of 
aspirin and thienopyridines. Aspirin, a cyclooxygenase-1-
selective inhibitor, when given to patients with ACS, results 
in a significant mortality benefit (Second International Study 
of Infarct Survival [ISIS-2]).11 The use of thienopyridines, 
which interfere with platelet aggregation by blocking the 
P2Y12 receptor on the platelet surface, has shown benefit 
when added to aspirin in this setting.12 Thus, the current 
standard of care for patients who present with ACS is a course 
of dual antiplatelet therapy, which usually is recommended 
ideally for up to 1 year following an acute event.13
Oral thienopyridines began with ticlopidine, a first-
generation thienopyridine, which although an effective 
agent for the irreversible blocking of the platelet P2Y12 
receptor, was found to have unfavorable side effects. The 
use of clopidogrel, a second-generation thienopyridine, 
almost completely replaced ticlopidine as the preferred 
P2Y12 inhibitor in ACS.14
Although clopidogrel is generally well tolerated, significant 
limitations remain, and there is an ongoing search for better 
and safer antiplatelet strategies. Because clopidogrel requires 
a bioconversion to its active metabolite, there is a delay in the 
onset of its antiplatelet activity; this can be partially overcome 
with a higher loading dose. In addition, a certain percent-
age of the population carries a reduced-function allele of 
the CYP2C19 gene and subsequently has reduced conversion 
of prodrug to active metabolite. The irreversible nature of its 
antiplatelet action also raises concerns for increased bleeding 
risk and typically results in delays in coronary artery bypass 
grafting (CABG) or noncardiac   operation.15 Furthermore, 
it has been well recognized that some patients will have a 
poor or variable response to clopidogrel.16 Although platelet 
function testing can identify the in vitro platelet response to 
P2Y12 inhibitors, there is as yet no general agreement on 
which platelet assay provides the best method for predicting 
subsequent clinical events. Therefore, practical utility of such 
testing in tailoring antiplatelet therapy remains uncertain, 
pending the results of larger outcome trials.17
More recently, a newer third-generation thienopyridine, 
prasugrel, was evaluated in a large trial and was found to be 
an effective therapy.18 However, concern regarding the higher 
bleeding risk observed with this drug has resulted in the need 
for the development of additional novel oral antiplatelet 
agents.19,20 The ideal antiplatelet agent would have a rapid 
onset and offset of action, not require metabolic conversion 
via hepatic pathways susceptible to the influence of other 
drugs or genetic variation, and an acceptable safety profile 
with a wide therapeutic window.
Pharmacology/mechanism of action
Ticagrelor is a member of a class of agents known as the 
cyclopentyl-triazolo-pyrimidines. These agents are relatively 
resistant to enzymatic degradation by ectonucleotidases, which 
rapidly degrade adenosine triphosphate (ATP) in vivo. Resis-
tance to this enzymatic degradation is critical because although 
ATP serves as a natural competitive antagonist to adenosine 
diphosphate (ADP) at the P2Y12 receptor, it is not a useful 
pharmacologic approach to P2Y12 antagonism secondary in 
part to its poor stability.21 Efforts to develop stable ATP ana-
logs led to the discovery of cangrelor. Further modifications 
of this molecule included the elimination of phosphates and 
a change in the core purine and sugar moieties, leading to the 
development of ticagrelor. It is not considered an ATP analog 
because of the changes in the purine and sugar moieties.
Ticagrelor is the most clinically advanced P2Y12 inhibitor 
in its class, and its chemical structure distinguishes it from the 
thienopyridines. Similar to the currently available irreversible 
P2Y12 inhibitors, ticagrelor is orally active and is selective for 
the P2Y12 receptor.22 However, in contrast to thienopyridine 
agents, it is a reversible inhibitor of the P2Y12, which may 
afford specific advantages and perhaps disadvantages.
Ticagrelor exerts its action via binding to the P2Y12 recep-
tor in a manner distinct from ADP, resulting in a reversible 
conformational change of the receptor (Figure 1). The ligand 
inhibition of the ADP receptor and subsequent signaling affect 
downstream processes. These include the conversion of cyclic Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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monophosphate from ATP, dephosphorylation of phospho-
rylated vasodilator-stimulated phosphoprotein (VASP), and 
activation of phosphoinositide 3-kinase. Inhibition of these 
processes results in reduced exposure of fibrinogen-binding 
sites to the GP IIb/IIIa receptor and thereby impairment of 
platelet aggregation.23 Interestingly, ticagrelor inhibits plate-
let aggregation despite increasing concentrations of ADP, 
demonstrating that this receptor inhibition is noncompetitive. 
Therefore, even in the setting of increased ADP concentra-
tions, there would be no reduction in the level of platelet inhi-
bition. Likewise, the effects of ticagrelor on platelet function 
correlate with plasma drug concentrations.23,24 In addition, 
ticagrelor’s effects on nonplatelet-bound ADP receptors may 
also produce off-target effects on vascular smooth muscle via 
inhibition of vasoconstriction. Coronary blood flow through 
inhibition of adenosine uptake by erythrocytes may also be 
affected.25–27 These pleiotropic effects together with ticagre-
lor’s unique reversible inhibition of the P2Y12 receptor may 
result in both unique advantages and disadvantages.
Pharmacokinetics
Ticagrelor is rapidly absorbed following oral administra-
tion with a median time to peak plasma concentration of 
1.3–2 hours.28 It is metabolized by CYP3A to an equipo-
tent active metabolite (AR-C124910XX) that is present at 
approximately one-third of the concentration of ticagrelor.29 
The formation of this active metabolite is rapid, and peak 
concentrations are reached in a median time of 1.5–3 hours. 
However, in contrast to the thienopyridines, metabolic activation 
is not required for inhibition of platelet aggregation (IPA), thus 
making it less susceptible to clinically significant drug–drug 
interactions or pharmacogenetic influences. The plasma con-
centrations (area under the curve [AUC] and maximum plasma 
concentration [Cmax]) of both ticagrelor and its metabolite are 
dose proportional and linear when administered as a single 
dose ranging from 30 to 400 mg. When steady-state studies 
were conducted (measurements at days 14 and 28) with doses 
of 100 mg twice daily, similar pharmacokinetics were found. 
However, when administered at long-term doses of 200 mg 
twice daily or 400 mg once daily, ticagrelor exhibited greater 
than dose-proportional kinetics with dose-normalized AUCs 
that were ∼50% more than dose proportional. This suggests 
that accumulation can occur at higher doses. In none of the 
aforementioned studies, were the pharmacokinetic variables 
of ticagrelor or   AR-C124910XX affected by age or gender.28,30 
In addition, there was no effect when administered with a 
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Figure 1 A and B) ADP binds to the P2Y12 receptor, resulting in conformational change and G-protein activation. C) Binding of the clopidogrel active metabolite to the 
P2Y12 receptor is irreversible, rendering the receptor nonfunctional for the life of the platelet. D) Ticagrelor binds reversibly to P2Y12 at a site distinct from the ADP-
binding site and inhibits ADP signaling and receptor conformational change by “locking” the receptor in an inactive state; the receptor is functional after dissociation of the 
ticagrelor molecule. ADP can still bind at its binding site, and the degree of receptor inhibition (and inhibition of ADP-induced signaling) is dependant on the concentration 
of ticagrelor. Copyright © 2009. Reproduced with permission from Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc 
Ther. 2009;27:259–274.
Abbreviation: ADP, adenosine diphosphate.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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high-fat meal.29 The terminal plasma half-life of both ticagre-
lor and its active metabolite, AR-C124910XX, is 6.6–12 and 
8.5–10 hours, respectively. This supports twice-daily dosing 
to maintain a steady-state plasma concentration.
Ticagrelor and AR-C124910XX are further metabolized 
into inactive metabolites and a glucuronide derivative, which 
are eliminated in the urine. However, the majority of both 
ticagrelor and AR-C124910XX are eliminated in the feces, 
making the need for adjustment in renal disease unlikely. It is 
unknown whether dose modification or concern is warranted 
in patients with significant liver disease or in those receiving 
potent inhibitors or inducers of CYP3A.
Pharmacodynamics
The pharmacodynamic response to P2Y12 inhibitors can be 
measured by several different methods. Traditionally, one 
of the most accepted methods has been light transmittance 
aggregometry. Preclinical studies of ticagrelor used whole 
blood impedance aggregometry. In clinical trials, optical 
aggregometry was adopted as the optimal technique for mea-
suring the IPA.28 In single-dose studies ranging from 100 to 
400 mg, the IPA was dose and time dependent and was nearly 
complete at 2 hours with a mean IPA of 88%–95% with 20 µM 
of ADP. The IPA gradually declined around 12-hours postdose 
as plasma concentrations declined, confirming that the IPA was 
reversible.30 Despite this, the IPA 24-hours postdose is still at 
least equivalent to, and in some cases higher than, clopidogrel 
75 mg.30,31 With multiple-dose studies, the final extent of IPA 
with 100 mg twice-daily dosing of ticagrelor is ∼90% at steady 
state. In patients with ACS receiving low-dose aspirin, a slightly 
lower dose of ticagrelor 90 mg twice daily produced the final 
extent of IPA that was ∼80% at 4 weeks. Although the IPA is 
dose related, doses higher than 90–100 mg twice daily result 
in only minimal increases in IPA. This suggests that higher 
doses may not result in any greater efficacy but may expose the 
patient to greater safety and/or tolerability concerns. Although 
interpatient variability in IPA response exists with ticagrelor, 
it is less than that of clopidogrel when a higher initial dose (ie, 
loading dose) and   twice-daily administration are utilized. For 
example, a 180-mg loading dose of ticagrelor led to a .70% 
IPA at 2 hours in 90% of patients compared with 16% for a 
600-mg loading dose of clopidogrel.32 A recently completed 
trial in which clopidogrel nonresponders and responders were 
switched to ticagrelor revealed that ticagrelor overcame non-
responsiveness to clopidogrel. In fact, the resulting antiplatelet 
effect in nonresponders was found to be the same as in 
responders. Furthermore, .98% of patients had platelet 
reactivity below the   levels   associated with ischemic risk 
while on ticagrelor (vs 44%–76% of those on clopidogrel).33 
Another unique property of ticagrelor is its reversible 
inhibition of the P2Y12 receptor that leads to a more rapid 
offset of IPA after discontinuation when   compared with 
clopidogrel. In the ONSET/OFFSET study, (Randamized 
Double-Blind Assessment of the ONSET and OFFSET of 
the Antiplatelet Effects of Ticagrelor Versus Clopidogrel 
in Patients with Stable Coronary Artery Disease),34 both 
ticagrelor and clopidogrel were discontinued after 6 weeks. 
Three days after the drugs were discontinued, the IPA in the 
ticagrelor group was comparable with the IPA measured at 
5 days postclopidogrel. The IPA measured at 5 days post-
ticagrelor discontinuation was similar to the IPA measured 
at 7 days following clopidogrel withdrawal. The potential 
clinical implications of this are discussed later.
In summary, the pharmacodynamic effects of ticagrelor as 
measured by IPA are rapid, high, and consistent. They are of 
sufficient duration when given twice daily and less susceptible 
to interpatient variability than currently available P2Y12 inhibi-
tors. The overall clinical benefit (ie, ischemic events vs bleeding) 
of ticagrelor over currently available oral antiplatelet therapies 
is an area of current investigation.
Clinical studies
Phase 1 trials
There have been a number of trials conducted in healthy sub-
jects to evaluate the pharmacokinetic or pharmacodynamic 
effects and general tolerability of ticagrelor and its active 
metabolite, AR-C124910XX. Table 1 includes a summary of 
the pertinent phase I trials that directly compare ticagrelor 
with placebo, clopidogrel, or aspirin.28,34–39
Phase ii trials
The phase II clinical trials, Dose confirmation Study assessing 
anti-Platelet Effects of AZD6140 vs clopidogRel in non-ST-
segment Elevation myocardial infarction (DISPERSE) and 
DISPERSE-2, and subsequent substudies evaluated the phar-
macokinetic or pharmacodynamic effects, clinical effects, 
and safety of ticagrelor in patients with stable atheroscle-
rosis and non-ST-segment elevation ACS (NSTE-ACS).29,40 
A summary of phase II trials is presented in Table 2.
DiSPeRSe trial
The DISPERSE trial30 was a multicenter, multinational, ran-
domized, double-blind, double-dummy, parallel-group study 
to assess ticagrelor pharmacokinetic or   pharmacodynamic Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Table 1 Summary of phase 1 trials with ticagrelor in healthy human subjects
Reference 
(patients)
Ticagrelor  
(dosing)
Comparator End point Main findings
Peters34 (2004)  
N = 13
30, 100, 200, 300, and  
400 mg once daily;  
escalating one-time  
single dose × 8 treatment  
periods of 7-d duration
Placebo Ticagrelor and  
AR-C124910XX Cmax,  
Tmax, AUC0–∞, t1/2, platelet 
aggregation (maximal  
and final inhibition),  
bleeding time, adverse  
events, vital signs, eCG,  
clinical chemistry and  
hematology, Holter  
monitoring, urinalysis,  
examination for petechia
Ticagrelor exhibits rapid and linear absorption 
with rapid formation of AR-C124910XX  
(active metabolite) and dose-proportional  
Cmax and AUC (ticagrelor and AR-C124910XX): 
mean range of ticagrelor parameters – Cmax 
(ng/mL), 161–2711; tmax (h), 1.5; AUC0–∞  
(ng h/mL), 1005–18,547; CL/F (mL/min kg), 
6.7–5; t1/2 (h), 7.3–8.9; mean range of  
AR-C124910XX parameters – Cmax (ng/mL), 
42–713; tmax (h), 1.5–3; AUC0–∞ (ng h/mL), 
376–6577; t1/2 (h), 8.5–10.1
Ticagrelor ($30 mg) platelet inhibition (IPA) 
was dose related, rapid, sustained up to 4 h 
(plateau effect, 100–400 mg near 100% IPA), 
and reversible at 12–24 h: 2 h (mean 
78%–95%; final extent with 20 µM ADP),  
4 h (65%–95%; final extent with 20 µM 
ADP), 12 h (35%–89%; final extent with 
20 µM ADP), and 24 h (10%–85%; final 
extent with 20 µM ADP)
Subjects experienced prolonged bleeding time  
after administration of ticagrelor independent  
of dose. Bleeding time varied amongst and  
between subjects: mean bleeding time  
increases 2 h postdose (100–400 mg;  
2.5–7.4 fold) and 4 h postdose  
(100–400 mg; 1.9–3.8 fold)
Adverse events: no apparent dose 
relationship, 13 with $1 adverse event,  
and mild purpura most common (placebo  
55%; 30 mg 20%–40%; 100 mg 60%–67%;  
200 mg 63%; 300 mg 38%; 400 mg 29%)
Study treatment discontinuation: 1 subject  
experienced syncope 10 d after ticagrelor  
administration and felt unrelated to  
treatment
Peters35 (2006)  
(N = 46)
50, 100, and 200 mg  
once daily or twice  
daily; 200, 300, 400,  
and 600 mg once daily;  
or 50, 100, 200, and  
300 mg twice daily;  
ascending dosing  
every 5 d
Clopidogrel  
300-mg LD,  
then 75 mg  
once daily;  
14 d
Cmax, Tmax, Css, AUC,  
t1/2, platelet aggregation  
(ticagrelor day 5,  
clopidogrel days 1 and 14), 
mean bleeding time,  
vital signs, eCG,  
laboratory tests
Ticagrelor demonstrated rapid onset with  
dose-dependent Cmax and AUC. Ticagrelor  
pharmacokinetic parameters: Tmax, 1.5–3 h;  
Css, 2–3 d; and mean t1/2, 6–13 h 
Ticagrelor inhibited platelet aggregation in a  
dose- and time-dependent manner (all doses)  
and to a greater degree with less variability  
than clopidogrel (doses $100 mg twice daily  
and $300 mg once daily): iPA 97%–100%  
throughout entire dosing; interval  
(ticagrelor 300 mg twice daily); 4 h mean  
iPA 67%; range 0%–100% and 90%; range  
13%–100% (clopidogrel day 1 and day 14)
Mean bleeding time: placebo (1.1–1.2 fold), 
ticagrelor (1.1–3.3 fold), and clopidogrel  
(1.5–1.9 fold)
Adverse events: no dose-related adverse  
events or clinically important effects on vital 
signs, eCG, laboratory tests reported
(Continued )Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Table 1 (Continued)
Reference 
(patients)
Ticagrelor  
(dosing)
Comparator End point Main findings
Butler36 (2007)  
(N = 14)
50 mg twice daily (1–5 d);  
200 mg twice daily (6–9 d); 
200 mg once daily (10 d);  
and 10-d treatment ×  
2 – period 1 = (+) aspirin  
and period 2 = (−) aspirin
Aspirin 300 mg  
once daily;  
10 d
Cmax, AUC, platelet  
aggregation, tolerability
Pharmacokinetics for ticagrelor and  
AR-C124910XX (active metabolite): Cmax and  
AUC for all ticagrelor doses; unaffected  
by concomitant; and aspirin therapy 
Pharmacodynamics of ticagrelor: rate, extent, 
and duration of iPA; unaffected by 
concurrent aspirin; aspirin increased 
collagen-induced platelet aggregation  
(eg, ticagrelor 200 mg alone 20% and  
ticagrelor 200 mg with aspirin 76%)  
reflecting combined antiplatelet effects
Tolerability: all doses tolerated with or 
without concurrent aspirin therapy
Butler37 (2008)  
(N = 6)
Single 200 mg14 
C-ticagrelor suspension
Placebo Radioactive dose  
recovered percent, mean  
radioactivity, plasma or  
blood ratio, major  
radioactive components  
by location, mean total  
amounts unchanged  
in urine
Ticagrelor was extensively metabolized with  
total recovery of radioactive dose: average  
84.3% (26.5% in urine and 57.8% in feces) 
Ticagrelor radioactivity restricted primarily to 
plasma space: mean radioactivity; plasma  
or blood ratio 1.69.
Major radioactive components in feces and 
plasma: AZD6140 and AR-C124910XX 
(active metabolite) Major radioactive 
components in urine: AR-C133913XX and 
its glucuronide conjugate
Exposure to active compounds unlikely affected 
by renal impairment as determined by mean 
total amounts unchanged AZD6140 and 
AR-C124910XX excreted in urine: 0.02% and 
0.04% of total dose
Butler38 (2008)  
(N = 48)
50, 100, 200, 300,  
400, and 600 mg  
once daily or twice  
daily; 14 d
Clopidogrel  
300-mg  
LD, then  
75 mg once  
daily; 14 d
Ticagrelor and  
AR-C124910XX Cmax,  
Tmax, AUC0–∞, t1/2,  
ticagrelor and clopidogrel  
platelet aggregation
Ticagrelor exhibited rapid absorption with 
dose-proportional Cmax and AUC ticagrelor and 
AR-C124910XX across all doses: mean Tmax, 
1.5–3 h; mean accumulation ratios, 1.2–1.8
Ticagrelor ($100 mg twice daily, 300 mg once 
daily) inhibited platelet aggregation over the 
entire dosing interval to a greater degree, with 
less variability than clopidogrel. Twice-daily dose 
of ticagrelor was more effective than the once 
daily: ticagrelor trough mean iPA 93%–99% 
vs clopidogrel 70%
Adverse events: no safety or tolerability 
issues reported
aTeng39 (2008) 
(N = NA)
900–1260 mg  
once daily; escalating  
one-time single  
dose × 8 treatment  
periods of 7-d duration
None Ticagrelor and  
AR-C124910XX Cmax,  
Tmax, AUC0–∞, t1/2, platelet  
aggregation (maximal  
and final inhibition),  
bleeding time, adverse  
events, vital signs, eCG,  
clinical chemistry and  
hematology, Holter  
monitoring, urinalysis,  
examination for petechia
Adverse events: no safety or tolerability  
issues reported up to 900 mg; dose-limiting  
gastrointestinal adverse events were  
observed (nausea, vomiting, and  
abdominal pain) at 1260 mg
Teng28 (2010) 
(N = 25)
0.1, 0.3, 1, 3, 10,  
30, and 100 mg;
Placebo Ticagrelor Cmax, Tmax,  
AUC0–∞, t1/2, platelet
Ticagrelor exhibited dose-proportional Cmax  
and AUC. Plasma levels were unquantifiable
(Continued )Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Table 1 (Continued)
Reference 
(patients)
Ticagrelor  
(dosing)
Comparator End point Main findings
escalating one-time  
single dose × 8  
treatment periods  
of 7-d duration
aggregation (maximal  
and final inhibition),  
bleeding time, adverse  
events, vital signs, eCG,  
clinical chemistry and  
hematology, Holter  
monitoring, urinalysis,  
examination for petechia
for doses ,1 mg: mean range ticagrelor  
parameters – Cmax (ng/mL), 5–510; tmax (h),  
1.3–2.0; AUC0–∞ (ng h/mL), 25–3548; CL/F  
(mL/min kg), 8.2–6.6; t1/2 (h), 4.1–8.5 
No notable difference in mean bleeding time  
up to ticagrelor 10 mg compared with placebo, 
dose-dependent prolongation in bleeding time  
seen with 30 and 100 mg: mean bleeding  
time 2 h postdose (30 mg, 1.2–2.2 fold;  
100 mg, 4.0 fold), 4 h postdose (100 mg,  
3.2 fold), 12 h postdose (100 mg, 2.2 fold) 
Ticagrelor IPA incomplete across dosage range 
0.1–100 mg: none reported 
Adverse events: no apparent dose 
relationship; 24 with $1 adverse event; 
mild purpura most common (placebo 47%; 
0.1 mg 40%; 0.3 mg 0%; 1 mg 17%; 3 mg 
83%; 10 mg 67%; 30 mg 20%–40%)
Study treatment discontinuation: 2 subjects  
(accidental injury; lactic dehydrogenase,  
and aspartate aminotransferase); felt  
unrelated to treatment
Note: aComplete data not available in publication.
Abbreviations: Cmax, maximum plasma concentration; Tmax, time to maximum plasma concentration; AUC0–∞, area under the plasma curve concentration; t1/2, half-life 
of elimination; eCG, electrocardiogram; tmax, time to maximum concentration; CL/F, total plasma oral clearance; iPA, inhibition of platelet aggregation; ADP, adenosine 
diphosphate; LD, loading dose; Css, concentration steady state; NA, not available.
properties and safety and tolerability in patients with 
atherosclerosis. A total of 200 patients were randomized 
to receive ticagrelor 50 mg (n = 41), 100 mg (n = 39), or 
200 mg (n = 37) twice daily, 400 mg (n = 46) once daily, or 
clopidogrel 75 mg (n = 37) once daily for 28 days in addition 
to aspirin 75–100 mg once daily.
Inclusion criteria were a confirmed diagnosis of athero-
sclerotic disease and aspirin therapy at a dose of 75–100 mg 
once daily for at least 2 weeks or more before random-
ization. Exclusion criteria included the presence of ACS 
within 3 months (or percutaneous coronary intervention 
[PCI] within 4 months) of randomization, increased risk 
of bleeding, elevated serum creatinine (screening creati-
nine .1.2 times the upper limit of normal), low hemoglobin 
level ($5% below the lower limit of normal), or platelet 
count ,125,000/mm3, active liver disease (or indication of 
liver disease on laboratory screening), and anticoagulant or 
antiplatelet (other than aspirin) use within 10 or 7 days of 
randomization.
Measured outcomes included inhibition of ADP-induced 
platelet aggregation using optical aggregometry of platelet-
rich plasma (final and maximal extent aggregation in response 
to 20 µM ADP), bleeding time, time dependent–drug plasma 
concentrations (AUC, Cmax, time to maximum concentration 
[tmax], half-life of elimination [t1/2], total plasma oral clear-
ance [CL/F] – all reported as a function of gender or age 
[#65 years and .65 years]), primary tolerability (reported 
incidence of adverse events, with bleeding complications 
classified as major or minor), electrocardiogram (ECG), 
vital sign, and clinical laboratory changes.
Ticagrelor significantly inhibited the ADP-induced plate-
let aggregation at 2 hours postdose on day 1 and at steady 
state (days 14 and 28). Platelet inhibition was more rapid 
with ticagrelor than clopidogrel and was to a greater extent 
with the doses of 100 mg twice daily, 200 mg twice daily, 
and 400 mg once daily. Ticagrelor’s effect on ADP-induced 
platelet aggregation was 24%–31% greater than clopidogrel 
for all 3 doses. Adequate platelet inhibition was maintained 
throughout the dosing interval with reduced IPA response 
variability, particularly with ticagrelor dosed twice daily. 
Platelet inhibition declined 24 hours after the last dose 
of ticagrelor indicating reversibility. However, IPA levels 
remained higher in the ticagrelor than clopidogrel group at 
24 hours after the last dose, effectively challenging concerns 
over whether a single missed dose of ticagrelor is clinically 
significant.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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l
o
r
 
a
n
d
 
c
l
o
p
i
d
o
g
r
e
l
,
 
r
e
s
p
e
c
t
i
v
e
l
y
)
.
 
i
n
 
a
d
d
i
t
i
o
n
,
 
9
.
9
%
 
p
a
t
i
e
n
t
s
 
t
r
e
a
t
e
d
 
w
i
t
h
 
t
i
c
a
g
r
e
l
o
r
 
1
8
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
 
e
x
p
e
r
i
e
n
c
e
d
 
m
o
s
t
l
y
 
a
s
y
m
p
t
o
m
a
t
i
c
 
v
e
n
t
r
i
c
u
l
a
r
 
p
a
u
s
e
s
 
a
t
 
l
e
a
s
t
 
 
o
n
c
e
 
l
a
s
t
i
n
g
 
.
2
.
5
s
.
 
O
v
e
r
a
l
l
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
 
r
a
t
e
s
 
w
e
r
e
 
s
i
m
i
l
a
r
 
f
o
r
 
a
l
l
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
(
c
l
o
p
i
d
o
g
r
e
l
 
6
%
;
 
t
i
c
a
g
r
e
l
o
r
 
9
0
 
m
g
 
6
%
;
 
a
n
d
 
t
i
c
a
g
r
e
l
o
r
 
1
8
0
 
m
g
 
7
%
)
.
R
e
S
P
O
N
D
3
3
 
 
(
R
,
 
D
B
,
 
M
C
,
 
a
n
d
 
C
r
o
s
s
 
o
v
e
r
)
 
N
 
=
 
9
8
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
s
t
a
b
l
e
 
C
A
D
i
n
c
l
u
s
i
o
n
:
 
a
g
e
 
$
1
8
;
 
d
o
c
u
m
e
n
t
e
d
 
s
t
a
b
l
e
 
 
C
A
D
 
a
n
d
 
o
n
 
a
s
p
i
r
i
n
 
t
h
e
r
a
p
y
 
7
5
–
1
0
0
 
m
g
 
d
a
i
l
y
e
x
c
l
u
s
i
o
n
:
 
A
C
S
 
w
i
t
h
i
n
 
t
h
e
 
p
a
s
t
 
1
2
 
m
o
,
 
 
a
 
h
i
s
t
o
r
y
 
o
f
 
b
l
e
e
d
i
n
g
 
d
i
a
t
h
e
s
i
s
 
o
r
 
s
e
v
e
r
e
 
 
p
u
l
m
o
n
a
r
y
 
d
i
s
e
a
s
e
,
 
p
r
e
g
n
a
n
c
y
,
 
c
u
r
r
e
n
t
 
 
s
m
o
k
i
n
g
 
(
.
1
 
p
a
c
k
 
p
e
r
 
d
a
y
)
,
 
c
o
n
c
o
m
i
t
a
n
t
 
 
t
h
e
r
a
p
y
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
o
r
 
s
t
r
o
n
g
 
C
Y
P
3
A
 
i
n
h
i
b
i
t
o
r
s
 
o
r
 
s
t
r
o
n
g
 
C
Y
P
3
A
 
i
n
d
u
c
e
r
s
 
w
i
t
h
i
n
 
 
1
4
 
d
 
o
f
 
t
h
e
 
s
t
u
d
y
,
 
p
l
a
t
e
l
e
t
 
c
o
u
n
t
 
 
,
1
0
0
,
0
0
0
 
m
m
3
 
o
r
 
h
e
m
o
g
l
o
b
i
n
 
,
1
0
 
g
/
d
L
,
 
 
d
i
a
b
e
t
e
s
 
w
i
t
h
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
 
$
1
0
%
,
 
h
i
s
t
o
r
y
 
 
o
f
 
d
r
u
g
 
a
d
d
i
c
t
i
o
n
 
o
r
 
a
l
c
o
h
o
l
 
a
b
u
s
e
 
i
n
 
t
h
e
 
 
p
a
s
t
 
2
 
y
,
 
N
S
A
i
D
s
,
 
a
n
d
 
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
 
,
3
0
 
m
L
/
m
i
n
A
l
l
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
c
l
o
p
i
d
o
g
r
e
l
 
 
3
0
0
 
m
g
 
d
a
i
l
y
 
t
o
 
a
s
s
e
s
s
 
 
c
l
o
p
i
d
o
g
r
e
l
 
r
e
s
p
o
n
s
i
v
e
n
e
s
s
,
 
t
h
e
n
 
 
w
e
r
e
 
r
a
n
d
o
m
i
z
e
d
 
t
o
 
6
0
0
 
m
g
 
 
c
l
o
p
i
d
o
g
r
e
l
 
f
o
l
l
o
w
e
d
 
b
y
 
7
5
 
m
g
 
 
d
a
i
l
y
 
o
r
 
t
i
c
a
g
r
e
l
o
r
 
1
8
0
 
m
g
 
 
f
o
l
l
o
w
e
d
 
b
y
 
9
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
 
 
f
o
r
 
∼
2
 
w
k
 
A
f
t
e
r
 
2
 
w
k
,
 
a
l
l
 
n
o
n
r
e
s
p
o
n
d
e
r
s
 
 
(
n
 
=
 
4
1
)
 
s
w
i
t
c
h
e
d
 
g
r
o
u
p
s
,
 
 
w
h
e
r
e
a
s
 
h
a
l
f
 
o
f
 
r
e
s
p
o
n
d
e
r
s
 
 
(
n
 
=
 
5
7
)
 
c
o
n
t
i
n
u
e
d
 
a
s
s
i
g
n
e
d
 
 
t
h
e
r
a
p
y
 
a
n
d
 
t
h
e
 
o
t
h
e
r
 
h
a
l
f
 
 
s
w
i
t
c
h
e
d
 
t
h
e
r
a
p
y
 
A
l
l
 
p
a
t
i
e
n
t
s
 
 
r
e
c
e
i
v
e
d
 
a
s
p
i
r
i
n
 
7
5
–
1
0
0
 
m
g
 
d
a
i
l
y
T
h
e
 
p
r
i
m
a
r
y
 
o
b
j
e
c
t
i
v
e
 
w
a
s
 
t
o
 
 
d
e
t
e
r
m
i
n
e
 
t
h
e
 
p
r
o
p
o
r
t
i
o
n
 
o
f
 
 
c
l
o
p
i
d
o
g
r
e
l
 
n
o
n
r
e
s
p
o
n
d
e
r
s
 
w
h
o
 
 
c
o
n
v
e
r
t
e
d
 
t
o
 
r
e
s
p
o
n
d
e
r
s
 
w
i
t
h
 
 
t
i
c
a
g
r
e
l
o
r
 
O
t
h
e
r
 
a
n
a
l
y
s
e
s
 
i
n
c
l
u
d
e
d
 
 
m
e
a
s
u
r
e
m
e
n
t
s
 
o
f
 
p
l
a
t
e
l
e
t
 
 
f
u
n
c
t
i
o
n
 
(
i
P
A
,
 
P
R
U
,
 
P
R
i
,
 
a
n
d
 
 
p
l
a
t
e
l
e
t
 
r
e
c
e
p
t
o
r
 
e
x
p
r
e
s
s
i
o
n
)
 
 
d
u
r
i
n
g
 
s
w
i
t
c
h
i
n
g
 
b
e
t
w
e
e
n
 
 
c
l
o
p
i
d
o
g
r
e
l
 
 
a
n
d
 
t
i
c
a
g
r
e
l
o
r
H
i
g
h
e
r
 
l
e
v
e
l
s
 
o
f
 
p
l
a
t
e
l
e
t
 
a
g
g
r
e
g
a
t
i
o
n
 
r
e
d
u
c
t
i
o
n
 
w
e
r
e
 
a
c
h
i
e
v
e
d
 
i
n
 
n
o
n
r
e
s
p
o
n
d
e
r
s
 
t
r
e
a
t
e
d
 
w
i
t
h
 
t
i
c
a
g
r
e
l
o
r
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
c
l
o
p
i
d
o
g
r
e
l
 
(
P
 
,
 
0
.
0
5
)
.
 
A
 
l
a
r
g
e
r
 
p
o
r
t
i
o
n
 
o
f
 
n
o
n
r
e
s
p
o
n
d
e
r
s
 
e
x
p
e
r
i
e
n
c
e
d
 
r
e
d
u
c
t
i
o
n
 
i
n
 
p
l
a
t
e
l
e
t
 
a
g
g
r
e
g
a
t
i
o
n
 
o
f
 
.
1
0
%
,
 
3
0
%
,
 
a
n
d
 
5
0
%
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
c
l
o
p
i
d
o
g
r
e
l
.
S
w
i
t
c
h
i
n
g
 
f
r
o
m
 
c
l
o
p
i
d
o
g
r
e
l
 
t
o
 
t
i
c
a
g
r
e
l
o
r
 
r
e
d
u
c
e
d
 
p
l
a
t
e
l
e
t
 
a
g
g
r
e
g
a
t
i
o
n
 
f
r
o
m
 
5
9
%
 
±
 
9
%
 
t
o
 
3
5
%
 
±
 
1
1
%
 
(
P
 
,
 
0
.
0
0
0
1
)
,
 
w
h
e
r
e
a
s
 
s
w
i
t
c
h
i
n
g
 
f
r
o
m
 
t
i
c
a
g
r
e
l
o
r
 
t
o
 
c
l
o
p
i
d
o
g
r
e
l
 
r
e
s
u
l
t
e
d
 
i
n
 
t
h
e
 
o
p
p
o
s
i
t
e
 
e
f
f
e
c
t
 
w
i
t
h
 
a
 
c
h
a
n
g
e
 
i
n
 
p
l
a
t
e
l
e
t
 
a
g
g
r
e
g
a
t
i
o
n
 
f
r
o
m
 
3
6
%
 
±
 
1
4
%
 
t
o
 
5
6
%
 
±
 
9
%
 
(
P
 
,
 
0
.
0
0
0
1
)
.
 
R
e
s
u
l
t
s
 
w
e
r
e
 
s
i
m
i
l
a
r
 
i
n
 
t
h
e
 
r
e
s
p
o
n
d
e
r
s
’
 
c
o
h
o
r
t
,
 
w
h
e
r
e
 
p
l
a
t
e
l
e
t
 
a
g
g
r
e
g
a
t
i
o
n
 
w
a
s
 
c
o
n
s
i
s
t
e
n
t
l
y
 
l
o
w
e
r
 
i
n
 
t
h
e
 
t
i
c
a
g
r
e
l
o
r
 
g
r
o
u
p
.
T
h
e
 
s
t
u
d
y
 
w
a
s
 
u
n
d
e
r
p
o
w
e
r
e
d
 
t
o
 
e
v
a
l
u
a
t
e
 
s
a
f
e
t
y
 
a
n
d
 
t
o
l
e
r
a
b
i
l
i
t
y
;
 
h
o
w
e
v
e
r
,
 
4
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
s
 
o
c
c
u
r
r
e
d
 
(
1
 
m
a
j
o
r
 
a
n
d
 
3
 
m
i
n
o
r
)
,
 
a
l
l
 
w
h
i
l
e
 
o
n
 
t
i
c
a
g
r
e
l
o
r
 
t
r
e
a
t
m
e
n
t
,
 
a
n
d
 
d
y
s
p
n
e
a
 
w
a
s
 
r
e
p
o
r
t
e
d
 
i
n
 
1
3
 
p
a
t
i
e
n
t
s
 
t
r
e
a
t
e
d
 
w
i
t
h
 
t
i
c
a
g
r
e
l
o
r
 
a
n
d
 
4
 
w
i
t
h
 
c
l
o
p
i
d
o
g
r
e
l
.
 
M
o
s
t
 
e
p
i
s
o
d
e
s
 
o
c
c
u
r
r
e
d
 
e
a
r
l
y
 
a
n
d
 
r
e
s
o
l
v
e
d
 
w
i
t
h
o
u
t
 
i
n
t
e
r
v
e
n
t
i
o
n
 
o
r
 
d
i
s
c
o
n
t
i
n
u
a
t
i
o
n
 
o
f
 
t
h
e
r
a
p
y
.
O
N
S
e
T
/
O
F
F
S
e
T
3
2
 
 
(
R
,
 
D
B
,
 
M
C
,
 
P
C
)
 
N
 
=
 
1
2
3
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
s
t
a
b
l
e
 
 
C
A
D
i
n
c
l
u
s
i
o
n
:
 
A
g
e
 
$
1
8
;
 
d
o
c
u
m
e
n
t
e
d
 
s
t
a
b
l
e
 
C
A
D
 
 
a
n
d
 
o
n
 
a
s
p
i
r
i
n
 
t
h
e
r
a
p
y
 
7
5
–
1
0
0
 
m
g
 
d
a
i
l
y
 
e
x
c
l
u
s
i
o
n
:
 
A
C
S
 
i
n
 
t
h
e
 
p
r
e
v
i
o
u
s
 
1
2
 
m
o
,
 
a
n
y
 
 
i
n
d
i
c
a
t
i
o
n
 
f
o
r
 
a
n
t
i
t
h
r
o
m
b
o
t
i
c
 
t
h
e
r
a
p
y
 
(
e
g
,
 
a
t
r
i
a
l
 
fi
b
r
i
l
l
a
t
i
o
n
,
 
p
r
o
s
t
h
e
t
i
c
 
h
e
a
r
t
 
v
a
l
v
e
,
 
o
r
 
c
o
r
o
n
a
r
y
 
 
s
t
e
n
t
)
,
 
c
o
n
g
e
s
t
i
v
e
 
h
e
a
r
t
 
f
a
i
l
u
r
e
,
 
l
e
f
t
 
v
e
n
t
r
i
c
u
l
a
r
 
 
e
j
e
c
t
i
o
n
 
f
r
a
c
t
i
o
n
 
,
3
5
%
,
 
f
o
r
c
e
d
 
e
x
p
i
r
a
t
o
r
y
 
 
v
o
l
u
m
e
 
i
n
 
t
h
e
 
fi
r
s
t
 
s
e
c
o
n
d
 
o
r
 
f
o
r
c
e
d
 
v
i
t
a
l
 
c
a
p
a
c
i
t
y
 
b
e
l
o
w
 
t
h
e
 
l
o
w
e
r
 
l
i
m
i
t
s
 
o
f
 
n
o
r
m
a
l
,
 
 
b
l
e
e
d
i
n
g
 
d
i
a
t
h
e
s
i
s
 
o
r
 
s
e
v
e
r
e
 
p
u
l
m
o
n
a
r
y
 
d
i
s
e
a
s
e
,
 
 
T
i
c
a
g
r
e
l
o
r
 
1
8
0
 
m
g
 
f
o
l
l
o
w
e
d
 
b
y
 
 
9
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
 
(
n
 
=
 
5
7
)
 
o
r
 
 
c
l
o
p
i
d
o
g
r
e
l
 
6
0
0
 
m
g
 
f
o
l
l
o
w
e
d
 
b
y
 
 
7
5
 
m
g
 
d
a
i
l
y
 
(
n
 
=
 
5
4
)
 
o
r
 
p
l
a
c
e
b
o
 
 
(
n
 
=
 
1
2
)
 
f
o
r
 
6
 
w
k
A
l
l
 
p
a
t
i
e
n
t
s
 
r
e
c
e
i
v
e
d
 
a
s
p
i
r
i
n
 
 
7
5
–
1
0
0
 
m
g
 
d
a
i
l
y
P
r
i
m
a
r
y
 
e
n
d
 
p
o
i
n
t
s
 
i
n
c
l
u
d
e
d
 
i
P
A
 
 
a
t
 
2
 
h
 
a
f
t
e
r
 
fi
r
s
t
 
d
o
s
e
 
a
n
d
 
t
h
e
 
 
s
l
o
p
e
 
o
f
 
i
P
A
 
b
e
t
w
e
e
n
 
4
 
 
a
n
d
 
7
2
 
h
 
a
f
t
e
r
 
l
a
s
t
 
d
o
s
e
 
S
e
c
o
n
d
a
r
y
 
e
n
d
 
p
o
i
n
t
s
 
i
n
c
l
u
d
e
d
 
 
i
P
A
,
 
c
o
l
l
a
g
e
n
-
i
n
d
u
c
e
d
 
l
i
g
h
t
-
 
t
r
a
n
s
m
i
t
t
a
n
c
e
 
a
g
g
r
e
g
o
m
e
t
r
y
,
 
 
P
R
i
,
 
A
D
P
-
i
n
d
u
c
e
d
 
G
P
 
i
i
b
/
i
i
i
a
,
a
n
d
 
P
-
s
e
l
e
c
t
i
n
 
e
x
p
r
e
s
s
i
o
n
,
 
P
R
U
 
 
a
n
d
 
p
e
r
c
e
n
t
 
i
n
h
i
b
i
t
i
o
n
 
m
e
a
s
u
r
e
d
 
 
O
N
S
e
T
:
 
T
i
c
a
g
r
e
l
o
r
 
1
8
0
-
m
g
 
L
D
 
p
r
o
d
u
c
e
d
 
a
 
g
r
e
a
t
e
r
 
d
e
g
r
e
e
 
o
f
 
p
l
a
t
e
l
e
t
 
i
n
h
i
b
i
t
i
o
n
 
t
h
a
n
 
c
l
o
p
i
d
o
g
r
e
l
 
6
0
0
-
m
g
 
L
D
 
a
t
 
0
.
5
 
a
n
d
 
2
 
h
 
(
4
1
%
 
a
n
d
 
8
8
%
 
v
s
 
8
%
 
a
n
d
 
3
8
%
,
 
r
e
s
p
e
c
t
i
v
e
l
y
;
 
P
 
,
 
0
.
0
0
0
1
)
 
a
n
d
 
a
t
 
a
l
l
 
t
i
m
e
s
 
t
h
r
o
u
g
h
o
u
t
 
t
h
e
 
2
4
-
h
 
p
e
r
i
o
d
.
 
T
h
e
 
r
a
t
e
 
o
f
 
o
n
s
e
t
 
(
s
l
o
p
e
)
 
o
f
 
t
h
e
 
a
n
t
i
p
l
a
t
e
l
e
t
 
e
f
f
e
c
t
 
c
u
r
v
e
 
f
r
o
m
 
0
 
t
o
 
2
 
h
 
a
s
 
a
s
s
e
s
s
e
d
 
b
y
 
i
P
A
 
w
a
s
 
m
o
r
e
 
r
a
p
i
d
 
w
i
t
h
 
t
i
c
a
g
r
e
l
o
r
 
t
h
a
n
 
c
l
o
p
i
d
o
g
r
e
l
 
(
4
3
.
5
7
%
 
v
s
 
1
9
.
4
5
%
 
i
P
A
/
h
;
 
P
 
,
 
0
.
0
0
0
1
)
.
 
O
F
F
S
E
T
:
 
T
h
e
 
l
e
v
e
l
 
o
f
 
I
P
A
 
a
c
h
i
e
v
e
d
 
w
a
s
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
h
i
g
h
e
r
 
i
n
 
t
h
e
 
t
i
c
a
g
r
e
l
o
r
 
g
r
o
u
p
 
t
h
a
n
 
t
h
e
 
c
l
o
p
i
d
o
g
r
e
l
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
2
 
(
C
o
n
t
i
n
u
e
d
)
T
r
i
a
l
/
d
e
s
i
g
n
M
a
j
o
r
 
i
n
c
l
u
s
i
o
n
/
e
x
c
l
u
s
i
o
n
 
 
c
r
i
t
e
r
i
a
S
t
u
d
y
 
r
e
g
i
m
e
n
M
a
j
o
r
 
e
n
d
 
p
o
i
n
t
s
M
a
i
n
 
fi
n
d
i
n
g
s
p
r
e
g
n
a
n
c
y
,
 
c
u
r
r
e
n
t
 
s
m
o
k
i
n
g
,
 
c
o
n
c
o
m
i
t
a
n
t
 
 
t
h
e
r
a
p
y
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
o
r
 
s
t
r
o
n
g
 
c
a
p
a
c
i
t
y
 
b
e
l
o
w
 
t
h
e
 
l
o
w
e
r
 
l
i
m
i
t
s
 
o
f
 
n
o
r
m
a
l
,
 
 
b
l
e
e
d
i
n
g
 
d
i
a
t
h
e
s
i
s
 
o
r
 
s
e
v
e
r
e
 
p
u
l
m
o
n
a
r
y
 
d
i
s
e
a
s
e
,
 
 
p
r
e
g
n
a
n
c
y
,
 
c
u
r
r
e
n
t
 
s
m
o
k
i
n
g
,
 
c
o
n
c
o
m
i
t
a
n
t
 
 
t
h
e
r
a
p
y
 
w
i
t
h
 
m
o
d
e
r
a
t
e
 
o
r
 
s
t
r
o
n
g
 
 
C
Y
P
3
A
4
 
i
n
h
i
b
i
t
o
r
s
 
o
r
 
s
t
r
o
n
g
 
C
Y
P
3
A
4
 
 
i
n
d
u
c
e
r
s
,
 
p
l
a
t
e
l
e
t
 
c
o
u
n
t
 
,
1
0
0
,
0
0
0
 
m
m
3
,
 
 
h
e
m
o
g
l
o
b
i
n
 
,
1
0
 
g
/
d
L
,
 
h
e
m
o
g
l
o
b
i
n
 
A
1
c
 
$
1
0
%
,
 
 
h
i
s
t
o
r
y
 
o
f
 
d
r
u
g
 
a
d
d
i
c
t
i
o
n
 
o
r
 
a
l
c
o
h
o
l
 
a
b
u
s
e
 
i
n
 
 
t
h
e
 
p
a
s
t
 
2
 
y
,
 
n
e
e
d
 
f
o
r
 
N
S
A
i
D
s
,
 
o
r
 
c
r
e
a
t
i
n
i
n
e
 
 
c
l
e
a
r
a
n
c
e
 
,
3
0
 
m
L
/
m
i
n
b
y
 
v
e
r
i
f
y
N
o
w
 
P
2
Y
1
2
 
a
s
s
a
y
 
a
n
d
 
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
s
g
r
o
u
p
 
a
f
t
e
r
 
6
 
w
k
 
o
f
 
t
h
e
r
a
p
y
.
 
A
f
t
e
r
 
l
a
s
t
 
d
o
s
e
,
 
t
h
e
 
i
P
A
 
s
l
o
p
e
 
d
e
c
l
i
n
e
d
 
m
o
r
e
 
r
a
p
i
d
l
y
 
i
n
 
t
h
e
 
t
i
c
a
g
r
e
l
o
r
 
g
r
o
u
p
 
t
h
a
n
 
t
h
e
 
c
l
o
p
i
d
o
g
r
e
l
 
g
r
o
u
p
,
 
a
n
d
 
a
t
 
7
2
 
a
n
d
 
1
2
0
 
h
,
 
p
l
a
t
e
l
e
t
 
i
n
h
i
b
i
t
i
o
n
 
w
a
s
 
l
e
s
s
 
f
o
r
 
t
i
c
a
g
r
e
l
o
r
 
t
h
a
n
 
c
l
o
p
i
d
o
g
r
e
l
 
a
s
 
m
e
a
s
u
r
e
d
 
b
y
 
i
P
A
 
a
n
d
 
s
i
m
i
l
a
r
 
t
o
 
p
l
a
c
e
b
o
 
a
t
 
1
6
8
 
a
n
d
 
2
4
0
 
h
.
 
T
h
e
 
t
i
c
a
g
r
e
l
o
r
 
g
r
o
u
p
 
e
x
p
e
r
i
e
n
c
e
d
 
g
r
e
a
t
e
r
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
 
r
a
t
e
s
 
t
h
a
n
 
c
l
o
p
i
d
o
g
r
e
l
 
o
r
 
p
l
a
c
e
b
o
 
(
2
8
.
1
%
 
v
s
 
1
3
.
0
%
 
v
s
 
8
.
3
%
)
.
 
M
o
s
t
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
s
 
w
e
r
e
 
c
l
a
s
s
i
fi
e
d
 
a
s
 
m
i
n
i
m
a
l
.
 
D
y
s
p
n
e
a
 
o
c
c
u
r
r
e
d
 
m
o
r
e
 
f
r
e
q
u
e
n
t
l
y
 
i
n
 
t
i
c
a
g
r
e
l
o
r
 
(
2
5
%
)
 
t
h
a
n
 
c
l
o
p
i
d
o
g
r
e
l
 
(
4
%
)
 
o
r
 
p
l
a
c
e
b
o
 
(
0
%
)
 
(
2
5
%
 
v
s
 
4
%
;
 
P
 
,
 
0
.
0
1
)
.
 
O
v
e
r
a
l
l
,
 
5
 
p
a
t
i
e
n
t
s
 
(
4
 
r
e
c
e
i
v
i
n
g
 
t
i
c
a
g
r
e
l
o
r
 
a
n
d
 
 
1
 
p
l
a
c
e
b
o
)
 
d
i
s
c
o
n
t
i
n
u
e
d
 
t
h
e
r
a
p
y
 
b
e
f
o
r
e
 
c
o
m
p
l
e
t
i
n
g
 
t
h
e
 
s
t
u
d
y
 
o
f
 
w
h
i
c
h
 
3
 
d
u
e
 
t
o
 
d
y
s
p
n
e
a
 
w
i
t
h
 
t
i
c
a
g
r
e
l
o
r
.
P
L
A
T
O
4
5
 
N
 
=
 
1
8
,
6
2
4
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
A
C
S
i
n
c
l
u
s
i
o
n
:
 
h
o
s
p
i
t
a
l
i
z
e
d
 
f
o
r
 
A
C
S
 
w
i
t
h
 
o
n
s
e
t
 
o
f
 
 
s
y
m
p
t
o
m
s
 
w
i
t
h
i
n
 
p
r
e
v
i
o
u
s
 
2
4
 
h
.
 
F
o
r
 
p
a
t
i
e
n
t
s
 
 
w
i
t
h
 
N
S
T
e
-
A
C
S
,
 
2
 
o
f
 
3
 
c
r
i
t
e
r
i
a
 
h
a
d
 
t
o
 
b
e
 
m
e
t
:
 
 
S
T
-
s
e
g
m
e
n
t
 
c
h
a
n
g
e
s
 
o
n
 
e
C
G
 
i
n
d
i
c
a
t
i
n
g
 
i
s
c
h
e
m
i
a
,
 
 
p
o
s
i
t
i
v
e
 
t
e
s
t
 
o
f
 
a
 
b
i
o
m
a
r
k
e
r
 
i
n
d
i
c
a
t
i
n
g
 
m
y
o
c
a
r
d
i
a
l
 
 
n
e
c
r
o
s
i
s
,
 
o
r
 
o
n
e
 
o
f
 
t
h
e
 
s
e
v
e
r
a
l
 
r
i
s
k
 
f
a
c
t
o
r
s
 
 
(
a
g
e
 
$
6
0
 
y
;
 
p
r
e
v
i
o
u
s
 
M
i
 
o
r
 
C
A
B
G
;
 
C
A
D
 
w
i
t
h
 
 
$
5
0
%
 
s
t
e
n
o
s
i
s
 
i
n
 
a
t
 
l
e
a
s
t
 
2
 
v
e
s
s
e
l
s
;
 
p
r
e
v
i
o
u
s
 
 
i
s
c
h
e
m
i
c
 
s
t
r
o
k
e
,
 
h
o
s
p
i
t
a
l
-
b
a
s
e
d
 
d
i
a
g
n
o
s
i
s
 
o
f
 
 
t
r
a
n
s
i
e
n
t
 
i
s
c
h
e
m
i
c
 
a
t
t
a
c
k
,
 
$
5
0
%
 
c
a
r
o
t
i
d
 
s
t
e
n
o
s
i
s
,
 
 
o
r
 
c
e
r
e
b
r
a
l
 
r
e
v
a
s
c
u
l
a
r
i
z
a
t
i
o
n
;
 
d
i
a
b
e
t
e
s
 
m
e
l
l
i
t
u
s
;
 
 
p
e
r
i
p
h
e
r
a
l
 
a
r
t
e
r
y
 
d
i
s
e
a
s
e
;
 
o
r
 
c
h
r
o
n
i
c
 
r
e
n
a
l
 
 
d
y
s
f
u
n
c
t
i
o
n
 
(
c
r
e
a
t
i
n
i
n
e
 
c
l
e
a
r
a
n
c
e
 
,
6
0
 
m
L
/
m
i
n
)
.
 
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
 
f
o
r
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
S
T
e
M
i
 
 
w
e
r
e
 
p
e
r
s
i
s
t
e
n
t
 
S
T
-
s
e
g
m
e
n
t
 
e
l
e
v
a
t
i
o
n
 
o
f
 
a
t
 
 
l
e
a
s
t
 
0
.
1
 
m
v
 
i
n
 
2
 
o
r
 
m
o
r
e
 
c
o
n
t
i
g
u
o
u
s
 
l
e
a
d
s
 
o
r
 
n
e
w
 
l
e
f
t
 
b
u
n
d
l
e
-
b
r
a
n
c
h
 
b
l
o
c
k
 
a
n
d
 
t
h
e
 
n
e
e
d
 
f
o
r
 
 
p
r
i
m
a
r
y
 
P
C
i
.
e
x
c
l
u
s
i
o
n
:
 
c
o
n
t
r
a
i
n
d
i
c
a
t
i
o
n
 
t
o
 
c
l
o
p
i
d
o
g
r
e
l
,
 
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
fi
b
r
i
n
o
l
y
t
i
c
 
d
r
u
g
s
 
w
i
t
h
i
n
 
2
4
 
h
 
 
a
f
t
e
r
 
r
a
n
d
o
m
i
z
a
t
i
o
n
,
 
n
e
e
d
 
f
o
r
 
o
r
a
l
 
a
n
t
i
c
o
a
g
u
l
a
n
t
 
 
d
r
u
g
s
,
 
a
n
 
a
c
u
t
e
 
c
o
m
p
l
i
c
a
t
i
o
n
 
o
f
 
P
C
i
 
(
i
n
d
e
x
 
 
e
v
e
n
t
)
,
 
P
C
i
 
d
o
n
e
 
a
f
t
e
r
 
t
h
e
 
i
n
d
e
x
 
e
v
e
n
t
 
b
u
t
 
 
b
e
f
o
r
e
 
fi
r
s
t
 
d
o
s
e
 
o
f
 
s
t
u
d
y
 
d
r
u
g
,
 
i
n
c
r
e
a
s
e
d
 
r
i
s
k
 
 
o
f
 
b
r
a
d
y
c
a
r
d
i
c
 
e
v
e
n
t
s
,
 
a
n
d
 
c
o
n
c
o
m
i
t
a
n
t
 
u
s
e
 
 
o
f
 
s
t
r
o
n
g
 
C
Y
P
3
A
 
i
n
h
i
b
i
t
o
r
s
 
o
r
 
i
n
d
u
c
e
r
s
S
t
a
n
d
a
r
d
 
t
h
e
r
a
p
y
 
i
n
c
l
u
d
i
n
g
 
a
s
p
i
r
i
n
 
 
a
n
d
 
e
i
t
h
e
r
 
t
i
c
a
g
r
e
l
o
r
 
1
8
0
 
m
g
 
 
f
o
l
l
o
w
e
d
 
b
y
 
9
0
 
m
g
 
t
w
i
c
e
 
d
a
i
l
y
 
o
r
 
 
L
D
 
o
f
 
c
l
o
p
i
d
o
g
r
e
l
 
3
0
0
–
6
0
0
 
m
g
 
 
f
o
l
l
o
w
e
d
 
b
y
 
7
5
 
m
g
 
d
a
i
l
y
 
f
o
r
 
u
p
 
 
t
o
 
1
2
 
m
o
P
r
i
m
a
r
y
 
e
f
fi
c
a
c
y
 
e
n
d
 
p
o
i
n
t
 
o
f
 
 
t
i
m
e
 
t
o
 
fi
r
s
t
 
o
c
c
u
r
r
e
n
c
e
 
o
f
 
t
h
e
 
 
c
o
m
p
o
s
i
t
e
 
o
f
 
d
e
a
t
h
 
f
r
o
m
 
v
a
s
c
u
l
a
r
 
 
c
a
u
s
e
s
,
 
M
i
,
 
o
r
 
s
t
r
o
k
e
.
 
S
e
c
o
n
d
a
r
y
 
 
e
f
fi
c
a
c
y
 
e
n
d
 
p
o
i
n
t
 
w
a
s
 
t
h
e
 
p
r
i
m
a
r
y
 
e
f
fi
c
a
c
y
 
v
a
r
i
a
b
l
e
 
 
s
t
u
d
i
e
d
 
i
n
 
s
u
b
g
r
o
u
p
 
o
f
 
p
a
t
i
e
n
t
s
 
i
n
 
w
h
o
m
 
i
n
v
a
s
i
v
e
 
m
a
n
a
g
e
m
e
n
t
 
w
a
s
 
p
l
a
n
n
e
d
 
a
t
 
r
a
n
d
o
m
i
z
a
t
i
o
n
 
a
n
d
 
t
h
e
 
c
o
m
p
o
s
i
t
e
s
 
o
f
 
a
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
,
 
M
i
,
 
o
r
 
s
t
r
o
k
e
;
 
d
e
a
t
h
 
f
r
o
m
 
v
a
s
c
u
l
a
r
 
 
c
a
u
s
e
s
,
 
M
i
,
 
s
t
r
o
k
e
,
 
s
e
v
e
r
e
 
 
r
e
c
u
r
r
e
n
t
 
c
a
r
d
i
a
c
 
i
s
c
h
e
m
i
a
,
 
 
r
e
c
u
r
r
e
n
t
 
c
a
r
d
i
a
c
 
i
s
c
h
e
m
i
a
,
 
 
t
r
a
n
s
i
e
n
t
 
i
s
c
h
e
m
i
c
 
a
t
t
a
c
k
,
 
o
r
 
o
t
h
e
r
 
 
a
r
t
e
r
i
a
l
 
t
h
r
o
m
b
o
t
i
c
 
e
v
e
n
t
,
 
c
o
m
p
o
n
e
n
t
s
 
o
f
 
t
h
e
 
p
r
i
m
a
r
y
 
e
n
d
 
p
o
i
n
t
,
 
a
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
;
 
a
n
d
 
s
t
e
n
t
 
t
h
r
o
m
b
o
s
i
s
.
P
r
i
m
a
r
y
 
s
a
f
e
t
y
 
e
n
d
 
p
o
i
n
t
 
w
a
s
 
t
h
e
 
 
fi
r
s
t
 
o
c
c
u
r
r
e
n
c
e
 
o
f
 
a
n
y
 
m
a
j
o
r
 
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
.
A
d
d
i
t
i
o
n
a
l
 
s
a
f
e
t
y
 
e
n
d
 
p
o
i
n
t
s
 
 
i
n
c
l
u
d
e
d
 
m
i
n
o
r
 
b
l
e
e
d
i
n
g
,
 
d
y
s
p
n
e
a
,
 
 
b
r
a
d
y
a
r
r
h
y
t
h
m
i
a
,
 
o
t
h
e
r
 
c
l
i
n
i
c
a
l
 
 
a
d
v
e
r
s
e
 
e
v
e
n
t
,
 
a
n
d
 
r
e
s
u
l
t
s
 
o
f
 
 
l
a
b
o
r
a
t
o
r
y
 
s
a
f
e
t
y
 
t
e
s
t
s
.
T
h
e
 
p
r
i
m
a
r
y
 
c
o
m
p
o
s
i
t
e
 
e
n
d
 
p
o
i
n
t
 
w
a
s
 
r
e
d
u
c
e
d
 
i
n
 
f
a
v
o
r
 
o
f
 
t
i
c
a
g
r
e
l
o
r
 
a
t
 
1
2
 
m
o
 
(
9
.
8
%
 
v
s
 
1
1
.
7
%
;
 
H
R
 
=
 
0
.
8
4
;
 
9
5
%
 
C
i
,
 
0
.
7
7
–
0
.
9
2
;
 
P
 
,
 
0
.
0
0
1
)
 
w
i
t
h
 
i
m
p
r
o
v
e
d
 
o
u
t
c
o
m
e
s
 
a
c
h
i
e
v
e
d
 
b
y
 
3
0
 
d
 
(
4
.
8
%
 
v
s
 
5
.
4
%
;
 
H
R
 
=
 
0
.
8
8
;
 
9
5
%
 
C
i
,
 
0
.
7
7
–
1
.
0
0
;
 
P
 
=
 
0
.
0
4
5
)
.
 
i
n
 
a
d
d
i
t
i
o
n
,
 
t
i
c
a
g
r
e
l
o
r
 
r
e
s
u
l
t
e
d
 
i
n
 
a
 
s
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
r
e
d
u
c
t
i
o
n
 
i
n
 
b
o
t
h
 
c
a
r
d
i
o
v
a
s
c
u
l
a
r
 
m
o
r
t
a
l
i
t
y
 
(
4
.
0
%
 
v
s
 
5
.
1
%
;
 
H
R
 
=
 
0
.
7
9
;
 
9
5
%
 
C
i
,
 
0
.
6
9
–
0
.
9
1
)
 
a
n
d
 
a
l
l
-
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
 
(
4
.
5
%
 
v
s
 
5
.
9
%
;
 
H
R
 
=
 
0
.
7
8
;
 
9
5
%
 
C
i
,
 
0
.
6
9
–
0
.
9
8
;
 
P
 
,
 
0
.
0
0
1
)
.
 
T
h
e
 
i
n
c
i
d
e
n
c
e
 
o
f
 
s
t
e
n
t
 
t
h
r
o
m
b
o
s
i
s
 
(
d
e
fi
n
i
t
e
;
 
d
e
fi
n
i
t
e
 
o
r
 
p
r
o
b
a
b
l
e
;
 
a
n
d
 
d
e
fi
n
i
t
e
,
 
p
r
o
b
a
b
l
e
,
 
o
r
 
p
o
s
s
i
b
l
e
)
 
w
a
s
 
a
l
s
o
 
r
e
d
u
c
e
d
 
(
1
.
3
%
 
v
s
 
1
.
9
%
;
 
H
R
 
=
 
0
.
6
8
;
 
9
5
%
 
C
i
,
 
0
.
5
0
–
0
.
9
1
;
 
P
 
=
 
0
.
0
0
9
)
.
 
T
h
e
r
e
 
w
a
s
 
n
o
 
d
i
f
f
e
r
e
n
c
e
 
i
n
 
m
a
j
o
r
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
s
 
b
e
t
w
e
e
n
 
t
h
e
 
2
 
t
r
e
a
t
m
e
n
t
 
g
r
o
u
p
s
 
(
1
1
.
6
%
 
v
s
 
1
1
.
2
%
;
 
P
 
=
 
0
.
4
3
)
.
 
H
o
w
e
v
e
r
,
 
c
o
m
b
i
n
e
d
 
m
a
j
o
r
 
a
n
d
 
m
i
n
o
r
 
 
b
l
e
e
d
i
n
g
 
f
a
v
o
r
e
d
 
c
l
o
p
i
d
o
g
r
e
l
 
(
1
6
.
1
%
 
v
s
 
1
4
.
6
%
;
P
 
=
 
0
.
0
0
8
)
.
 
N
o
n
-
C
A
B
G
-
r
e
l
a
t
e
d
 
m
a
j
o
r
 
b
l
e
e
d
i
n
g
 
e
v
e
n
t
s
 
w
e
r
e
 
i
n
c
r
e
a
s
e
d
 
w
i
t
h
 
t
i
c
a
g
r
e
l
o
r
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
c
l
o
p
i
d
o
g
r
e
l
 
(
4
.
5
%
 
v
s
 
3
.
8
%
;
 
P
 
=
 
0
.
0
3
)
,
 
b
u
t
 
C
A
B
G
-
r
e
l
a
t
e
d
 
m
a
j
o
r
 
b
l
e
e
d
i
n
g
 
w
a
s
 
s
i
m
i
l
a
r
 
b
e
t
w
e
e
n
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Similar to findings reported in phase I trials, the rate 
and extent of ticagrelor’s maximum IPA (IPAmax) effect 
corresponded with time to maximum exposure (Tmax), with 
a plateau effect observed for doses .100 mg twice daily. 
Ticagrelor pharmacokinetic parameters were not affected 
by gender or age. These findings suggest ticagrelor 100 mg 
twice daily as a maintenance dose is as effective as higher 
doses and superior to clopidogrel at inhibiting platelet 
aggregation.
In the DISPERSE trial, patients receiving ticagrelor expe-
rienced an increased incidence of bleeding, primarily minor, 
resulting in discontinuation of treatments in 7 patients, of 
which 4 were receiving the 400 mg once-daily dose. In addi-
tion, bleeding times were prolonged in all patients receiving 
ticagrelor, independent of the dose; this prolongation was to 
a greater extent than noted with clopidogrel. Other adverse 
events included dizziness, headache, red blood cells in the 
urine, and dyspnea.
Dyspnea affected 10%–20% of patients taking ticagrelor 
and appeared to be dose related. All cases were classified as 
mild to moderate in severity, with only one resulting in treat-
ment discontinuation and none associated with heart failure 
or bronchospasm. In contrast to the findings reported in the 
literature, there were no reports of dyspnea in the clopidogrel 
treatment arm. Although the mechanism by which ticagrelor 
results in dyspnea is unknown, a number of theories have 
been proposed and debated.41–43 In addition, all ticagrelor 
groups exhibited an increase in uric acid levels of 5%–10% 
from baseline. Uric acid levels in patients taking clopidogrel 
decreased about 10%. One case of ticagrelor discontinuation 
was due to overdose, and 1 patient discontinued clopidogrel 
treatment due to polyarthritis. No quality of life or adherence 
data were reported.
In summary, in the DISPERSE trial, ticagrelor was gen-
erally well tolerated and exhibited more rapid, potent, and 
sustained inhibition of ADP-induced platelet aggregation 
compared with clopidogrel 75 mg once daily in patients with 
atherosclerosis taking aspirin. Although the effects of ticagre-
lor were rapidly reversible, it maintained the high levels of 
platelet inhibition 24 hours after the last dose of 100, 200, 
or 400 mg when compared with clopidogrel. Ticagrelor did 
increase bleeding and dyspnea, possibly in a dose-dependent 
manner, as well as uric acid levels, compared with clopi-
dogrel. These adverse effects, however, were mostly minor 
or mild to moderate in nature. Based on the reported findings 
of the study, the authors concluded that ticagrelor 100 and 
200 mg twice daily would be carried forward for future trials 
due to a favorable balance of safety and efficacy.
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DiSPeRSe-2 trial
The DISPERSE-2 trial40 was a multicenter, multinational, 
randomized (1:1:1), double-blinded, dose-confirmation trial 
to compare safety and efficacy of ticagrelor with clopidogrel 
in patients with NSTE-ACS. A total of 990 patients treated 
with aspirin, up to 325 mg initially, then 75–100 mg once 
daily; standard therapy of ACS, including β-blocker, statin, 
and parenteral anticoagulant ± GP IIb/IIIa inhibitor; and 
PCI or CABG, as clinically indicated, were randomized to 
receive ticagrelor 90 mg twice daily, 180 mg twice daily 
or clopidogrel 300 mg initially (unless already treated 
with clopidogrel) followed by 75 mg once daily for up to 
12 weeks. An additional clopidogrel 300-mg loading dose 
was allowed for patients scheduled to undergo PCI within 
48 hours of randomization. The ticagrelor group was sub-
randomized to receive a 270-mg loading dose or placebo.
Patients were included if they were hospitalized for 
NSTE-ACS within 48 hours, experiencing ischemic symp-
toms $10-minute duration at rest, with biochemical marker 
evidence of myocardial infarction (MI) or ischemia on ECG. 
Exclusion criteria included persistent ST-segment eleva-
tion within $20 minutes, .48 hours from symptom onset 
to expected therapy initiation, PCI within 48 hours before 
index event or randomization, recent CABG (3 months) or 
stroke (30 days) increased risk of bleeding, concomitant 
treatment with oral anticoagulants, daily nonsteroidal anti-
inflammatory drugs (NSAIDs), or thrombolysis for STEMI 
within the previous 7 days.
Measured outcomes included the following: (1) total 
bleeding events (major and minor bleeding) within the first 
4 weeks of treatment, (2) individual and composite incidence 
of MI (including silent MI), death, stroke, and severe recur-
rent ischemia, and (3) incidence of recurrent ischemia (total 
duration detected on Holter monitoring of ECG).
A total of 984 patients received at least 1 dose of study 
medication with scheduled treatment for 12 weeks (50%), 
8 weeks (25%), or 4 weeks (25%). Median duration of 
treatment was 56 days. Majority of the patients were men 
(64%), and the average age of the overall study population 
was 63 years. Approximately 24% of patients had diabetes, 
48% ST-segment depression, and 62% NSTE-ACS. Most 
patients received aspirin, heparin, statins, and β-blockers, 
and less than one-third received GP IIb/IIIa inhibitors. Over 
two-thirds of the patients underwent coronary angiography, 
with 42% receiving PCI (2% balloon angioplasty and 40% 
stenting, of which 48% were drug eluting) and 9% CABG.
There was no significant difference in the occurrence of the 
primary outcome of bleeding events at 4 weeks (clopidogrel 
8.1%, ticagrelor 90 mg 9.8%, and ticagrelor 180 mg 8.0%; 
P = 0.43 and P = 0.96 for comparisons between clopidogrel 
and ticagrelor, respectively) or secondary outcome of bleed-
ing events at 12 weeks (clopidogrel 9.9%, ticagrelor 90 mg 
10.9%, and ticagrelor 180 mg 11.4%; P = 0.62 and P = 0.72 
for comparisons between clopidogrel and ticagrelor, respec-
tively). Two patients suffered fatal bleeds in the ticagrelor 
90 mg group although overall rates of major bleeding events 
(fatal or life-threatening and others) were similar between 
these groups. Minor bleeding occurred more frequently 
in the ticagrelor 180 mg group than clopidogrel at both 4 
(clopidogrel 1.3%, ticagrelor 90 mg 2.7%, and ticagrelor 
180 mg 3.8%; P = 0.18 and P = 0.0504 for comparisons 
between clopidogrel and ticagrelor, respectively) and 12 
weeks (clopidogrel 1.3%, ticagrelor 90 mg 2.7%, and ticagre-
lor 180 mg 6.1%; P = 0.18 and P = 0.01 for comparisons 
between clopidogrel and ticagrelor, respectively).
The majority of all reported bleeding events occurred 
initially (within the first 4 weeks of treatment). In addition, 
during the first 48 hours of treatment, bleeding events were 
numerically more frequent both within the clopidogrel group 
(clopidogrel 2.8% major and minor and 2.4% major bleeds) 
and in patients who received ticagrelor 270-mg loading 
dose (3.6% major and minor and 1.8% major bleeds ) vs 
the ticagrelor 90 and 180 mg group who did not receive a 
loading dose (ticagrelor 90 mg 2.4% major and minor and 
1.3% major bleeds and ticagrelor 180 mg 1.3% major [no 
minor bleeds]).
Bleeding events were often procedure related (clopidogrel 
73%, ticagrelor 90 mg 53%, and ticagrelor 180 mg 52%) and 
most frequently periprocedural hemorrhage or hematoma. 
There was minimal difference in reported bleeding events 
requiring treatment discontinuation (clopidogrel 3 [0.9%], 
ticagrelor 90 mg 8 [2.4%], and ticagrelor 180 mg 5 [1.5%] 
patients) and/or blood transfusions (clopidogrel 22 [6.7%], 
ticagrelor 90 mg 24 [7.2%], and ticagrelor 180 mg 15 [4.6%] 
patients) amongst the clopidogrel or ticagrelor 90 mg and 
180 mg groups. For all patients undergoing CABG, incidence 
of bleeding was numerically greater in patients treated with 
clopidogrel (62%) than ticagrelor (43%), thus suggesting a 
theoretical advantage for ticagrelor-treated patients because 
of rapid reversal of platelet inhibition.
The potential advantage of ticagrelor over clopidogrel 
in patients undergoing CABG was further investigated in a 
post hoc DISPERSE-2 substudy published by Husted et al.44 
This study reported a nonstatistically significant reduction 
in CABG-related major bleeding for patients treated with 
ticagrelor compared with clopidogrel when therapy was Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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discontinued within 1–5 days of operation (36% vs 64%; 
P = 0.15). In addition, major bleeding event rates were 
similar in patients undergoing CABG whether treatment 
was discontinued ,1 day or .5 days before operation.15 
However, bleeding rates remained constant in clopidogrel-
treated patients independent of time to CABG, whereas 
bleeding rates in ticagrelor-treated patients increased when 
time to CABG exceeded 5 days compared with 1–5 days, 
which suggests a lack of comparability between treatment 
groups.15 In addition, CABG-related major bleeding rates 
should be viewed as hypothesis generating only, as the 
DISPERSE-2 trial was not prospectively designed to evalu-
ate these differences.
In the overall DISPERSE-2 trial, rates of MI were similar 
amongst all treatment groups, with a nonstatistically sig-
nificant trend toward a lower event rate in the ticagrelor 90 
and 180 mg groups compared with clopidogrel at 12 weeks 
(3.8%, 2.5%, vs 5.6%; P = 0.41 and P = 0.06 for comparisons 
between ticagrelor and clopidogrel, respectively) and a sig-
nificant reduction in the rate of MI at 4 weeks with ticagrelor 
180 mg (1% vs 3.5%; P = 0.047 for comparisons between 
ticagrelor and clopidogrel). The occurrence of MI in the 
ticagrelor groups was noted to be distributed throughout the 
study period. The composite of cardiovascular death, MI, or 
stroke was also similar for all 3 groups at 12 weeks (ticagrelor 
90 mg 6.0%, ticagrelor 180 mg 3.5%, and clopidogrel 6.2%; 
P = 0.9 and P = 0.12 for comparisons between ticagrelor and 
clopidogrel, respectively).
All treatments were generally well tolerated. Patients 
receiving ticagrelor 90 and 180 mg experienced a greater 
incidence of hypotension compared with clopidogrel (4.2%, 
3.7%, vs 0.6%; P = 0.004 and P = 0.01 for comparisons 
between ticagrelor and clopidogrel, respectively) and the 
ticagrelor 180 mg group experienced a greater incidence 
of diarrhea (7.4% vs 3.4%; P = 0.02) and dyspnea (15.8% 
vs 6.4%; P , 0.0002). The incidence of dyspnea in the 
ticagrelor 90 and 180 mg groups were also elevated com-
pared with clopidogrel (10.5%, 15.8%, vs 6.4%; P = 0.07 and 
P , 0.0002 for comparisons between ticagrelor and clopi-
dogrel, respectively). The increased incidence of dose-related 
dyspnea with ticagrelor compared with clopidogrel confirms 
the results of the DISPERSE trial. In combination, both trials 
suggest dyspnea is a dose-related adverse effect of ticagre-
lor that occurs occasionally and is of undetermined clinical 
importance. It should be noted that in the DISPERSE-2 trial, 
27% of patients who reported dyspnea had resolution within 
24 hours, 25% had resolution after 24 hours, and 48% had 
persistent symptoms beyond 15 days during treatment. This 
incidence of persistent dyspnea was 2% for clopidogrel and 
6% for either of the ticagrelor groups.
Nearly all patients (89.4%) underwent Holter monitoring 
in a post hoc analysis. No difference in the rates of ventricular 
arrhythmias (sustained ventricular tachycardia .30 seconds, 
any episode of nonsustained ventricular tachycardia, or 
any triplets) were identified; however, patients treated with 
ticagrelor 180 mg twice daily experienced mostly asymptom-
atic ventricular pauses lasting .2.5 seconds. These occurred 
at a rate of 9.9% for at least 1 pause and 4.9% for .3 epi-
sodes in the ticagrelor 180 mg group vs 5.5% and 2.0% in 
those receiving 90 mg and 4.3% and 0.3% in those receiving 
clopidogrel. The comparisons were statistically significant 
only for the ticagrelor 180 mg group vs clopidogrel.
Discontinuation rates were similar for all treatment groups 
(clopidogrel 6%, ticagrelor 90 mg 6%, and ticagrelor 180 mg 
7%). Ticagrelor discontinuation rates due to an adverse event 
were about 1%–4%. Information regarding patient adherence 
and quality of life measures was not reported.
In conclusion, the DISPERSE-2 trial demonstrated that 
the addition of ticagrelor 90 or 180 mg twice daily to aspirin, 
standard ACS therapies, and intervention when necessary in 
patients with NSTE-ACS was generally as safe as clopidogrel 
from a combined major and minor bleeding event standpoint. 
Additionally, most bleeding events occurred within the first 
28 days of treatment and were often procedure related. How-
ever, the ticagrelor groups did experience a small increase in 
the incidence of mild bleeding throughout the duration of the 
study. In addition, patients in the ticagrelor treatment groups 
did experience an increased incidence of dyspnea compared 
with clopidogrel, an unexpected finding of mostly asymp-
tomatic ventricular pauses lasting .2.5 seconds, hypoten-
sion, and mild increases in uric acid levels. It was postulated 
that these effects may be related to adenosine metabolism. 
Although the trial was not powered to evaluate the incidence 
of major adverse cardiovascular events, there appeared to be 
a dose-related trend in the reduction of MI throughout the 
study with ticagrelor. In addition, the pharmacokinetic and 
pharmacodynamic properties observed offered some sug-
gestions that ticagrelor may have an advantage in patients 
undergoing CABG or other surgical procedures.
In a substudy of the DISPERSE-2 trial published by   Storey 
et al,31 the antiplatelet effects of ticagrelor were assessed in 
“clopidogrel-pretreated” patients. Regardless of previous 
clopidogrel exposure, ticagrelor dose   dependently inhibited 
platelet aggregation to a greater degree than clopidogrel 300 
and 75 mg. IPA with ticagrelor was consistent throughout 
the duration of the study (eg, 4-hour postdose and day 28). Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Higher ticagrelor dosing also resulted in less interindividual 
variability. In addition, ticagrelor dose dependently inhibited 
platelet aggregation to a level not   previously achieved in all 
patients pretreated with clopidogrel, particularly those in the 
highest tertile of platelet aggregation at baseline. These findings 
indicate that treatment with ticagrelor resulted in comparable 
safety and tolerability to clopidogrel while achieving superior 
IPA independent of the clopidogrel “pretreatment” status.
Phase iii trials
Despite the apparent safety, tolerability, and efficacy signals 
of ticagrelor, questions remained regarding bleeding risk and 
the clinical implications of observed adverse events, includ-
ing asymptomatic ventricular pauses, hypotension, increased 
uric acid levels, and dyspnea. To further define the clinical 
role of ticagrelor in the treatment and prevention of cardio-
vascular disease, three phase III investigations, the PLATelet 
inhibition and patient Outcomes (PLATO), ONSET/OFFSET, 
and RESPOND (Response to Ticagrelor in Clopidogrel 
Nonresponders and Responders and Effect of Switching 
Therapies) trials, were performed.32,33,45 A summary of these 
phase III trials is included in Table 2.
PLATO trial
The PLATO trial was a multicenter, multinational, double-
blind, randomized trial to compare the efficacy and safety of 
ticagrelor and clopidogrel in patients hospitalized with ACS 
with or without STEMI.45
In the PLATO trial, 18,624 patients were randomized within 
24 hours of ACS to receive a ticagrelor 180-mg loading dose 
followed by 90 mg twice daily or clopidogrel 300-mg loading 
dose (600 mg optional) followed by clopidogrel 75 mg once 
daily for 6–12 months. If patients were taking clopidogrel for 
.5 days before randomization, the clopidogrel loading dose 
was avoided. Additional therapies included standard treatments 
for ACS (aspirin 75–100 mg once daily, 325 mg for 6 months if 
receiving drug-eluting stent [DES], and 325-mg loading dose 
for aspirin–naive patients), GP IIb/IIIa inhibitors, and parenteral 
  anticoagulants – oral anticoagulants were not allowed. Provision 
of an additional ticagrelor 90 mg or clopidogrel 300-mg loading 
dose for patients undergoing PCI 24 hours after randomization 
was allowed. For patients undergoing CABG, it was recom-
mended that clopidogrel be continued for 5 days and ticagrelor 
for 24–72 hours before the procedure.
Patients were eligible if they were hospitalized for ACS, 
with or without STEMI, with onset of symptoms within the 
previous 24 hours. For patients with NSTE-ACS, the follow-
ing 2 of 3 criteria had to be met: ST-segment changes on ECG 
indicating ischemia, positive test of a biomarker indicating 
myocardial necrosis, or one of the several risk factors (age 
$60 years; previous MI or CABG; CAD with $50% stenosis 
in at least two vessels; previous ischemic stroke, hospital-
based diagnosis of transient ischemic attack, $50% carotid 
stenosis, or cerebral revascularization; diabetes mellitus; 
peripheral artery disease; or chronic renal dysfunction [crea-
tinine clearance ,60 mL/min]). Inclusion criteria for patients 
with STEMI included persistent ST-segment elevation of at 
least 0.1 mV in two or more contiguous leads or new left 
bundle-branch block and the need for primary PCI.
Exclusion criteria included a contraindication to clopi-
dogrel, treatment with fibrinolytic drugs within 24 hours after 
randomization, need for oral anticoagulant drugs, an acute 
complication of PCI (index event), PCI done after the index 
event but before the first dose of study drug, increased risk of 
bradycardic events, and concomitant use of strong CYP3A 
inhibitors or inducers.
Measured outcomes were the primary efficacy end point 
of time to first occurrence of the composite of death due to 
vascular causes, MI, or stroke. The secondary efficacy end 
point was the primary efficacy variable studied in subgroup 
of patients in whom invasive management was planned at ran-
domization and the composites of all-cause mortality, MI, or 
stroke; death due to vascular causes, MI, stroke, severe recur-
rent cardiac ischemia, recurrent cardiac ischemia, transient 
ischemic attack, or other thrombotic event, components of the 
primary end point, all-cause mortality; and stent thrombosis. 
The primary safety end point was the first occurrence of any 
major bleeding event. Additional safety end points included 
minor bleeding, dyspnea, bradyarrhythmia, other clinical 
adverse event, and results of laboratory safety tests.
At time of randomization, the ticagrelor and clopidogrel 
groups had similar baseline characteristics, nonstudy medi-
cations, and procedures. Patient presentation included 43% 
NSTE-ACS, 38% STEMI, and 17% unstable angina with 
61% of patients undergoing PCI and ∼4.5% CABG during 
the index hospitalization. Study drug was initiated at a median 
of 11.3 hours (interquartile range [IQR] 4.8–19.8) after the 
start of chest pain. Most patients in the clopidogrel group 
received a loading dose of at least 300 mg (79.1%) with 
fewer patients receiving the higher dose of 600 mg (19.6%) 
between time of index event and up to 24 hours after random-
ization. Additional medical treatment was similar between 
the two groups. Median duration of study drug exposure was 
277 days (IQR 179–365).
The primary composite end point was reduced in favor 
of ticagrelor at 12 months (9.8% vs 11.7%; hazard ratio Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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[HR] = 0.84; 95% confidence interval [CI]: 0.77–0.92; 
P , 0.001) with improved outcomes achieved by 30 days 
(4.8% vs 5.4%; HR = 0.88; 95% CI: 0.77–1.00; P = 0.045). 
The trial results were driven by a reduction in MI and cardio-
vascular death but not stroke for which the ticagrelor group 
experienced more hemorrhagic and cryptogenic events. Most 
importantly, ticagrelor resulted in a statistically significant 
reduction in both cardiovascular mortality (4.0% vs 5.1%; 
HR = 0.79; 95% CI: 0.69–0.91) and all-cause mortality 
(4.5% vs 5.9%; HR = 0.78; 95% CI: 0.69–0.98; P , 0.001). 
PLATO was unique as this was the first trial of platelet 
P2Y12 inhibitors used in the setting of ACS to demonstrate 
a clear mortality benefit. The incidence of stent thrombosis 
(definite; definite or probable; and definite, probable, or 
possible) was also reduced (1.3% vs 1.9%; HR = 0.68; 95% 
CI: 0.50–0.91; P = 0.009). In addition, in a PLATO substudy 
analysis of all patients with planned invasive strategy per-
formed by Cannon and Harrington,46 the benefit of ticagrelor 
treatment extended to patients receiving DES. The results 
of the trial were consistent across ACS subtypes, multiple 
subgroups, and in patients with planned invasive strategy.46 
Ticagrelor did not improve outcomes in patients weighing 
less than their median weight by gender, patients not taking 
statins, and North American subjects.
There was no difference in major bleeding events between 
the 2 treatment groups (11.6% vs 11.2%; P = 0.43). However, 
combined major and minor bleeding favored clopidogrel 
(16.1% vs 14.6%; P = 0.008). Non-CABG-related major 
bleeding events were increased with ticagrelor compared 
with clopidogrel (4.5% vs 3.8%; P = 0.03). Unexpectedly, 
CABG-related major bleeding was similar between the 
2 groups, suggesting that the reversible nature of ticagrelor’s 
antiplatelet inhibition may confer some added safety com-
pared with the irreversible thienopyridines. More patients in 
the ticagrelor group experienced intracranial bleeding com-
pared with clopidogrel (26 [0.3%] vs 14 [0.2%]; P = 0.06) 
including fatal intracranial bleeding (11 [0.1%] vs 1 [0.01%]; 
P = 0.02). However, more patients in the clopidogrel group 
experienced nonintracranial fatal bleeding (21 [0.3%] vs 
9 [0.1%]; P = 0.03). Bleeding rates did not differ across 
most subgroups, except patients with a body mass index 
(BMI) .30 kg/m2 who experienced major bleeding more 
frequently with ticagrelor than with clopidogrel. Results were 
similar when applying thrombolysis in MI (TIMI) bleeding 
criteria. These findings are consistent with the DISPERSE-2 
trial and likely reflect differences in the pharmacokinetic and 
pharmacodynamic profiles of clopidogrel and ticagrelor as 
previously discussed.
Although ticagrelor was generally well tolerated, as pre-
viously reported, it was associated with increased incidence 
of dyspnea compared with clopidogrel (13.8% vs 7.8%; 
P , 0.001), which infrequently resulted in therapeutic 
discontinuation (0.9% vs 0.1%; P , 0.001). Patients in the 
ticagrelor group were also more likely to experience ven-
tricular pauses $3 seconds during the first week of therapy 
(no difference at 30 days) and increased serum uric acid and 
serum creatinine from baseline, which remained different 
throughout the study duration, but were no longer different 
1 month after study drug discontinuation. These findings 
confirmed previous reports of adverse events from phase II 
trials. The PLATO trial was of appropriate size and dura-
tion to evaluate the tolerability of ticagrelor compared with 
clopidogrel. Although the reported adverse events appear 
manageable, their clinical significance remains uncertain and 
will require further evaluation with continuous monitoring.
Treatment was prematurely discontinued more frequently 
in the ticagrelor group than the clopidogrel group (23.4% vs 
21.5%; P = 0.002), most likely due to an adverse event 
(7.4% vs 6.0%; P , 0.001) or unwillingness to continue the 
study drug (10.1% vs 9.2%; P = 0.04). Information regard-
ing quality of life was not reported. Overall adherence to the 
study drug was 82.8%.
The PLATO trial demonstrated that in a broad ACS 
population, ticagrelor added to standard therapy for up to 
12 months was more effective than clopidogrel in reduc-
ing death due to vascular causes, MI, and stroke while not 
increasing the risk of major bleeding. The net benefit pro-
vided by ticagrelor was instrumental in reducing all-cause 
mortality, a secondary outcome, which was appropriately 
tested as part of the hierarchal nature of the analysis. It is 
conceivable that the primary efficacy outcome may have been 
overestimated due to the low utilization of higher loading 
dose of clopidogrel. However, this strategy would likely be 
at the cost of increased bleeding events.
In addition to the PLATO trial in ACS, two recent clini-
cal trials, the RESPOND study and the ONSET/OFFSET 
trial, were performed to evaluate ticagrelor and clopidogrel 
dosing strategies in patients with stable CAD taking daily 
aspirin.32,33
ReSPOND study
The RESPOND study33 was a multicenter, multinational, 
randomized, double-blind, double-dummy, cross over 
investigation to compare the effects of ticagrelor with 
clopidogrel in patients with stable CAD taking aspirin 
who were identified either as nonresponders or responders Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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to clopidogrel. Response was assessed using a clopidogrel 
300-mg loading dose and defined based on 20 µmol/L ADP-
induced platelet aggregation measured before dosing and 
6–8 hours after dosing. Clopidogrel nonresponders were 
defined as those with absolute change in maximum platelet 
aggregation of ,10%.
A total of 98 patients (41 nonresponders and 57 respond-
ers) were randomized to receive a loading dose of ticagrelor 
180 mg followed by 90 mg twice daily or clopidogrel 600 mg 
followed by 75 mg once daily for 14 ± 2 days. At the end of 
first treatment period, patients switched therapies and began 
second treatment period lasting another 14 ± 2 days. Nonre-
sponders switched to the alternative treatment, whereas half 
of the responders switched and half continued the same regi-
men. Patients continuing the same regimen did not receive 
a second loading dose.
Patients aged $18 years with documented stable CAD 
who were taking aspirin 75–100 mg once daily were included. 
Exclusion criteria of patients included history of ACS within 
the past 12 months, history of bleeding diathesis or severe 
pulmonary disease, pregnancy, current smoking (.1 pack per 
day), concomitant therapy with moderate or strong CYP3A 
inhibitors or strong CYP3A inducers within 14 days of the 
study, platelet count ,100,000/mm3 or hemoglobin level 
,10 g/dL, diabetes with hemoglobin A1c $10%,   history 
of drug addiction or alcohol abuse in the past 2 years, non-
steroidal anti-inflammatory drug use, and creatinine clearance 
,30 mL/min.
The primary objective of the study was to determine 
the proportion of clopidogrel nonresponders who convert 
to responders with ticagrelor. The effects of study drug on 
markers of platelet inhibition were evaluated and included: 
IPA, P2Y12 reaction units (PRU), platelet reactivity index 
(PRI), and platelet receptor expression. Bleeding events were 
classified using PLATO criteria, and medication compliance 
was measured.
Patients were aged 45–85 years and primarily men. Base-
line demographics were similar between the 2 groups, except 
for a higher proportion of smokers in the responder group. 
As expected, higher levels of reduction in platelet aggrega-
tion were achieved in nonresponders treated with ticagrelor 
compared with clopidogrel (P , 0.05). A larger portion of 
nonresponders experienced reduction in platelet aggrega-
tion of .10%, 30%, and 50% compared with clopidogrel. 
Switching from clopidogrel to ticagrelor reduced platelet 
aggregation from 59% ± 9% to 35% ± 11% (P , 0.0001), 
whereas switching from ticagrelor to clopidogrel resulted 
in the opposite effect with a change in platelet aggregation 
from 36% ± 14% to 56% ± 9% (P , 0.0001). Results were 
similar in the responders’ cohort, where platelet aggregation 
was consistently lower in the ticagrelor group.
In both nonresponders and responders, the IPAmax was 
achieved more rapidly (1–2 hours) and to a greater extent 
with ticagrelor than with clopidogrel. Results were similar 
regardless of the treatment period. The highest levels of 
IPA occurred after switching from clopidogrel to ticagrelor, 
whereas switching from ticagrelor to clopidogrel resulted 
in an initial carryover effect that diminished by day 14. 
Finally, platelet reactivity was below cutoff points previously 
associated with ischemic risk measured by light transmit-
tance aggregometry, VerifyNow® (Accumetrics, San Diego, 
CA) P2Y12 assay, and VASP phosphorylation (VASP-P) in 
98%–100% of patients after ticagrelor treatment compared 
with 44%–70% with clopidogrel.
About 83% of nonresponders and 95% of responders 
completed the study. Reasons for study drug discontinuation 
in the 2 groups included adverse events (5 nonresponders and 
1 responder), noncompliance (1 nonresponder), and nontreat-
ment-related reasons (1 nonresponder and 2 responders). 
Four patients (2 clopidogrel responders and 2 clopidogrel 
nonresponders) experienced five serious adverse events (MI, 
hypotension, atrial fibrillation, and bradycardia) during or 
after ticagrelor therapy. One death occurred on day 30 of 
follow-up and was deemed unrelated to study treatment. Four 
bleeding events occurred (1 major and 3 minor), all while 
on ticagrelor treatment. Similar to previous reports, dyspnea 
was reported in 13 patients treated with ticagrelor and 4 
with clopidogrel. Most episodes occurred early and resolved 
without intervention or discontinuation of therapy.
The RESPOND study provides one of the first accounts 
of patient adherence with ticagrelor, which was similar 
between both groups at visit 3 (nonresponders 79% and 
responders 79%) and visit 5 (nonresponders 89% and 
responders 91%).
The RESPOND study demonstrated ticagrelor’s abil-
ity to inhibit platelet aggregation in patients with stable 
CAD previously identified as clopidogrel nonresponders. 
Ticagrelor not only produced greater reductions in platelet 
reactivity in both responders and nonresponders but also 
resulted in rapid and greater IPA in patients switching from 
clopidogrel to ticagrelor. The level of platelet aggrega-
tion achieved was also more consistently below ischemic 
cutoff points than clopidogrel as measured by a variety of 
assays. Based on the superior efficacy, ticagrelor may be 
considered, pending clinical outcome trials, as a favorable 
alternative in patients previously reported to be clopidogrel Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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nonresponders. The RESPOND study was underpowered 
to evaluate safety and tolerability. Therefore, a strategy of 
switching a patient from clopidogrel to ticagrelor should 
be pursued with caution.
ONSeT/OFFSeT trial
The ONSET/OFFSET trial32 was a multicenter, multinational, 
randomized, double-blind, double-dummy, parallel-group 
study to compare the onset and offset of IPA with ticagrelor 
using the PLATO trial’s loading dose (180 mg) with a high 
loading dose (600 mg) of clopidogrel in patients with stable 
CAD taking aspirin.
A total of 123 patients were randomized to receive 
ticagrelor 180-mg loading dose followed by 90 mg twice 
daily or clopidogrel 600-mg loading dose followed by 75 mg 
once daily or placebo in addition to aspirin 75–100 mg for 
6 weeks followed by a 10-day offset period.
Patients $18 years of age with documented CAD who 
were receiving aspirin therapy were included. Exclusion 
criteria included history of ACS in the previous 12 months, 
any indication for antithrombotic therapy (eg, atrial fibril-
lation, prosthetic heart valve, or coronary stent), congestive 
heart failure, left ventricular ejection fraction ,35%, forced 
expiratory volume (FEV) in the first second or forced vital 
capacity (FVC) below the lower limits of normal, bleeding 
diathesis or severe pulmonary disease, pregnancy, current 
smoking, concomitant therapy with moderate or strong 
CYP3A4 inhibitors or strong CYP3A4 inducers, platelet 
count ,100,000/mm3, hemoglobin ,10 g/dL, hemoglobin 
A1c $10%, history of drug addiction or alcohol abuse in the 
past 2 years, need for nonsteroidal anti-inflammatory drug, 
or creatinine clearance ,30 mL/min.
Primary end points of the ONSET study included IPA 
at 2 hours after first dose and the slope of IPA between 4 
and 72 hours after last dose. Secondary end points included 
a number of pharmacodynamic measures of platelet activ-
ity, including IPA, collagen-induced light transmittance 
aggregometry, PRI, ADP-induced GP IIb/IIIa, and P-selectin 
expression, PRU and percent inhibition measured by Veri-
fyNow P2Y12 assay; bleeding events as defined by PLATO 
criteria; and medication compliance.
A total of 57 patients were randomized to ticagrelor 
  treatment, 54 to clopidogrel, and 12 to placebo (52, 51, and 
11 patients in each group, respectively, completed the study). 
The patients were primarily white and aged 41–83 years. 
Baseline demographics were similar in all treatment groups 
(72% family history of CAD, 75% hypertension, 96% hyper-
lipidemia, and 45% prior MI).
ONSeT
A ticagrelor 180-mg loading dose produced a greater degree 
of platelet inhibition than clopidogrel 600-mg loading 
dose at 0.5 and 2 hours (41% and 88% vs 8% and 38%, 
  respectively; P , 0.0001) and at all times throughout the 
24-hour period. Additionally, the rate of onset (slope) of the 
antiplatelet effect curve from 0 to 2 hours as assessed by IPA 
was more rapid with ticagrelor than clopidogrel (43.57% vs 
19.45% IPA/h; P , 0.0001). In fact, within 1 hour of admin-
istration of a ticagrelor loading dose the IPA achieved was 
greater than the IPAmax eventually produced (7.8 hours) by 
the loading dose of clopidogrel. Ticagrelor produced an 
IPA max of 93% at 2 hours, which resulted in a larger portion 
of patients achieving .50% IPA (98% vs 31%; P , 0.0001) 
and .70% IPA (90% vs 16%; P , 0.0001) when compared 
with clopidogrel.
OFFSeT
The level of IPA achieved was significantly higher in the 
ticagrelor group than the clopidogrel group indicating sustained 
and consistent platelet inhibition after 6 weeks of therapy. After 
last dose, the IPA slope declined more rapidly in the ticagrelor 
group than the clopidogrel group. Importantly, at 24–48 hours, 
the level of IPA for ticagrelor and clopidogrel was not signifi-
cantly different. However, by 72 and 120 hours platelet inhibi-
tion was less for ticagrelor than clopidogrel as measured by IPA 
and similar to placebo by 168 and 240 hours. The rate of offset 
(slope of the antiplatelet effect curve) from 4 to 72 hours after 
last dose was more rapid in the ticagrelor group (−1.04% vs 
−0.48% IPA/h; P , 0.0001), resulting in a quicker reduction 
of IPA from 30% to 10% (53.30 hours vs 116.20 hours) and 
time to 10% IPA (109.19 hours vs 195.66 hours). Overall, IPA 
levels for ticagrelor and clopidogrel after last dose were similar 
at days 3 and 5 and days 5 and 7, respectively.
The ticagrelor group experienced greater bleeding event 
rates than clopidogrel or placebo (28.1%, 13.0%, vs 8.3%, 
respectively). Most bleeding events were classified as minimal. 
Dyspnea occurred more frequently in ticagrelor (25%) than 
clopidogrel (4%) or placebo (0%) (25% vs 4%; P , 0.01). 
Overall, 5 patients (4 receiving ticagrelor and 1 placebo) 
discontinued therapy before completing the study of which 
3 were due to dyspnea with ticagrelor. Throughout the trial, 
compliance rates were acceptable at .95%.
The results of the ONSET/OFFSET trial demonstrate 
that ticagrelor loading dose produces a more rapid and potent 
level of platelet inhibition compared with a high loading 
dose of clopidogrel in patients with stable CAD. The level of 
platelet inhibition achieved with ticagrelor was greater than Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
214
Birkeland et al
clopidogrel and sustained over a period of 6 weeks. In addi-
tion, ticagrelor’s reversible inhibition of platelets suggests a 
more rapid theoretical reversal of bleeding compared with 
clopidogrel after discontinuation of therapy at steady state, 
although the IPA levels did not become statistically significantly 
different until 72 hours. This was the first study to compare 
pharmacokinetic and pharmacodynamic effects of ticagrelor 
and clopidogrel immediately after dosing and using a strategy 
of the highest recommended dose for clopidogrel loading. 
Similar to the RESPOND trial and previous phase II studies, 
the ONSET/OFFSET trial was of short duration and not pow-
ered to evaluate the safety and tolerance of ticagrelor or the 
abrupt discontinuation of antiplatelet therapy in patients with   
stable CAD.
Patient-focused perspectives
To our knowledge, quality of life and satisfaction information 
in patients taking ticagrelor have not been published in the 
literature. In the PLATO substudy trial design, it was noted by 
James et al47 that quality of life was measured at time of hospital 
discharge. This information was not discussed by Cannon and 
Harrington.46 Medication adherence was acceptable in most 
clinical trials as discussed previously in this article. To our 
knowledge, there are no ongoing trials specifically designed to 
address these issues.
Dosing and administration
A range of ticagrelor dosing strategies has been investigated 
in phase I, II, and III clinical trials. Dosing will most likely 
be based on the regimen utilized in the PLATO trial. In 
patients with ACS undergoing PCI, the timing of ticagrelor 
dosing is important. Prior to PCI, a loading dose of 180 mg 
of ticagrelor should be administered 1–2 hours before the 
procedure then followed by 90 mg twice daily. In patients 
who have already received a loading dose .24 hours prior 
to PCI, an additional 90-mg loading dose may be given. Prior 
to CABG, ticagrelor should be discontinued for 72 hours and 
possibly longer based on the results of the ONSET/OFFSET 
trial. The recommended duration of therapy post-ACS will 
likely be up to 12 months.
Dosage reduction strategies were not evaluated in 
the phase III clinical trials. In PLATO trial, patients with 
a BMI .30 kg/m2 experienced a greater incidence of 
major bleeding events. Also, ticagrelor was not studied in 
patients with an estimated creatinine clearance ,30 mL/
min. Ticagrelor should be used cautiously in obese patients 
with ACS and avoided in patients with significant renal 
  dysfunction. Ticagrelor is significantly metabolized by the 
hepatic CYP3A4 and should be used with caution in patients 
with moderate or severe hepatic dysfunction.
Concomitant use of ticagrelor with moderate and strong 
CYP3A4 inhibitors, strong CYP3A4 inducers, and oral anti-
coagulants was not studied in clinical trials. Ticagrelor should 
not be administered in patients taking these therapies until 
additional information is available. In the PLATO trial, patients 
who were receiving therapy with strong CYP3A4 inhibitors, 
such as ketoconazole, itraconazole, voriconazole, telithromy-
cin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfina-
vir, indinavir, atazanavir, and grapefruit juice .1 L/d, CYP3A 
substrates with narrow therapeutic indices (cyclosporine and 
quinidine), or strong CYP3A inducers (rifampin or rifampi-
cin, phenytoin, and carbamazepine) were excluded. Aspirin, 
parenteral anticoagulants, and GP IIb/IIIa inhibitors were 
administered concomitantly with ticagrelor in patients with 
ACS. Dosing recommendations for standard therapies should 
be followed in accordance with established guidelines.
In ACS patients who are determined to be clopidogrel 
nonresponders, a strategy of replacing the clopidogrel 
with ticagrelor 180-mg loading dose followed by 90 mg 
twice daily after 24 hours appears attractive but needs to 
be evaluated in a properly powered clinical outcome trial. 
Replacement with ticagrelor may initially result in greater 
platelet inhibition than previously achieved and, thus, close 
monitoring and patient education are warranted.
Due to the twice daily dose administration requirements 
of ticagrelor medication, noncompliance has been raised as a 
concern. Based on the sustained antiplatelet effect of ticagre-
lor 24 hours after discontinuation of therapy, it is unlikely that 
a patient will experience a rebound effect. However, patients 
should be continually educated regarding the safety concerns 
and risks associated with medication noncompliance.
Safety and tolerability
Ticagrelor has been studied in a phase III clinical outcome 
trial of ACS.45 However, its efficacy and safety in other 
clinical situations (such as stable angina, elective PCI, and 
stroke) have not been evaluated in any clinical outcome trials. 
Therefore, its use in these situations cannot be recommended 
at this time. In addition, certain patient groups were excluded 
from the PLATO trial and, thus, should not be considered for 
treatment with ticagrelor without further study. This includes 
patients receiving fibrinolytic treatment within the previous 
24 hours, a need for oral anticoagulation, an increased risk 
for bradycardia, moderate to severe liver disease, need for 
dialysis, active bleeding or bleeding history, major operation 
within 30 days, pregnancy or lactation, clinically important Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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anemia or thrombocytopenia, and concomitant treatment 
with a strong CYP3A inhibitor or inducer. It should be used 
cautiously in patient receiving moderate CYP3A inhibitors 
or inducers.
The definition of bleeding in PLATO trial was more 
inclusive than either the TIMI or the Clopidogrel in Unstable 
angina to prevent Recurrent Events (CURE) protocols and 
was felt to more appropriately assess the bleeding risk of 
long-term antiplatelet therapy.47 Bleeding events were the 
primary safety end point, and major bleeding was defined as 
life-threatening, if it met the following criteria: fatal, intrac-
ranial, or pericardial (with cardiac tamponade, hypovolemia, 
and shock), or severe hypotension requiring resuscitation 
with vasopressors or operation (Table 3). In addition, it had 
to be associated with a decrease in the level of hemoglobin 
.5.0 g/dL, or a transfusion requirement of .4 U of whole 
blood or packed red blood cells. Other bleeding was con-
sidered major if it was associated with significant disability 
(such as intraocular bleeding with permanent vision loss) 
and accompanied by a 3.0–5.0 g/dL decrease in hemoglobin 
level or transfusion of 2–3 U of blood. Minor bleeding was 
defined as any hemorrhage requiring medical intervention, 
and a minimal bleeding was any bleed that did not require 
treatment. There was no overall difference in protocol 
defined or TIMI major bleeding between clopidogrel and 
ticagrelor. Ticagrelor was associated with a higher rate of 
non-CABG-related major bleeding and a greater number of 
fatal intracranial hemorrhages. There were fewer episodes 
of CABG-related major bleeds and fatal (nonintracranial) 
bleeding with ticagrelor. Of all the subgroups, there was 
no significant difference in bleeding risk except for het-
erogeneity with BMI, with an interaction P value of 0.05. 
Patients with a BMI $30 kg/m2 had less major bleeding 
with clopidogrel.
Although ticagrelor is a more potent antiplatelet agent 
than clopidogrel, no net increase in major bleeding was found 
in animal studies. It has been proposed that there is a wider 
separation of the anithrombotic effects from the bleeding risk 
with ticagrelor compared with thienopyridines.22 In rat and 
dog models, ticagrelor was able to achieve antithrombotic 
effects that surpassed thienopyridines without an equivalent 
elevation of the bleeding time.48
Typically, cardiovascular surgeons prefer to wait 5–7 days 
after withdrawal of a thienopyridine prior to CABG. The 
reversible inhibition of P2Y12 platelet receptors of ticagrelor 
has resulted in speculation that it may be a safer alternative 
for patients requiring earlier operations compared with 
thienopyridines.23 This advantage has not been realized, as 
there was no difference to ticagrelor over clopidogrel in terms 
of risk of major CABG-related bleeding in PLATO trial. In 
DISPERSE-2 study, there were numerically fewer major 
bleeds in patients undergoing CABG between 1 and 5 days 
after discontinuing these drugs, although the difference did 
not appear to be statistically significant.43 The primary end 
point for offset in the ONSET/OFFSET trial was the slope 
of the antiplatelet effect curve.32 This was assessed using 
20 µmol/L of ADP by light transmittance aggregometry 
(measured by IPA) and revealed a more rapid offset for 
ticagrelor compared with clopidogrel. However, it is also 
apparent that platelet inhibition (IPA) after study drug was 
discontinued did not become statistically significant until 
72 hours, and platelet inhibition assessed by VerifyNow 
and VASP-P never showed a statistical difference between 
ticagrelor and clopidogrel in the hours and days after study 
drug discontinuation. Thus, the hope that ticagrelor offers 
a significant advantage over thienopyridines in the first 
3 days after discontinuation has not been supported by the 
available data.
Ventricular pauses were seen more commonly with 
ticagrelor in clinical trials. A post hoc analysis of 
  DISPERSE-2 demonstrated a greater number of ventricu-
lar pauses in the ticagrelor group, which usually remained 
asymptomatic. Most pauses were reported to be due to sinus 
block or sinus exit block, although there were 4 patients who 
experienced complete heart block. In PLATO trial, Holter 
monitoring was performed during the initial week of therapy 
Table 3 Adverse events in PLATO bleeding
Event Ticagrelor Clopidogrel Hazard ratio P value
Major bleeding 961/9235 (11.6) 929/9186 (11.2) 1.04 (0.95–1.13) 0.43
Life-threatening bleed 491/9235 (5.8) 480/9186 (5.8) 1.03 (0.90–1.16) 0.70
Fatal bleed 20/9235 (0.3) 23/9186 (0.3) 0.87 (0.48–1.59) 0.66
intracranial bleed 26/9235 (0.3) 14/9186 (0.2) 1.87 (0.98–3.58) 0.06
Fatal intracranial bleed 11/9235 (0.1) 1/9186 (0.01) – 0.02
Non-CABG-related bleed 362/9235 (4.5) 306/9186 (3.8) 1.19 (1.02–1.38) 0.03
CABG-related bleed 619/9235 (7.4) 654/9186 (7.9) 0.95 (0.85–1.06) 0.32
Major or minor bleeding 1339/9235 (16.1) 1215/9186 (14.6) 1.11 (1.03–1.20) 0.008Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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and then was repeated at 30 days in a total of 1,991 patients 
(Table 4). Although a greater number of pauses lasting 
3   seconds or longer were seen in the ticagrelor group, there 
was no significant difference between the two groups. The 
pauses were rarely symptomatic, with no difference reported 
in the incidence of syncope, complete heart block, or pace-
maker insertion. About 90% of patients in both groups 
were given β-blockers either during hospitalization or at 
discharge. However, it is also important to remember that 
patients at an increased risk for bradycardia were excluded 
from the PLATO trial.
A prespecified subgroup analysis of the ONSET/
OFFSET trial evaluated cardiac and pulmonary function 
testing in 123 patients with stable CAD, who were given 
ticagrelor, clopidogrel, and placebo. Dyspnea was reported 
in 38.6% of patients receiving ticagrelor compared with 
9.3% of those receiving clopidogrel and 8.3% on placebo. 
Most patients (17 of 22) had symptoms develop within 
1 week of therapy with ticagrelor, and the dyspnea was 
usually described as mild. There were 3 (out of 57) patients 
who discontinued ticagrelor because of dyspnea, and there 
were 3 patients in the ticagrelor group whose dyspnea was 
persistent after ticagrelor withdrawal at the end of the 
study. However, it is important to note that the patients 
with a FEV in 1 second or a FVC below the lower limit of 
normal for age were excluded from this trial. No difference 
in any cardiopulmonary testing, including blood pressure, 
heart rate, ECG, echocardiogram, left ventricular ejection 
fraction, N-terminal probrain natriuretic peptide, oxygen 
saturation, or pulmonary function testing, was apparent 
among ticagrelor, clopidogrel, and placebo before, during, 
or after the 6-week study.49
The use of ticagrelor in the setting of pulmonary disease 
has not been prospectively studied. There was a 13.8% 
incidence of dyspnea in the PLATO trial in those   receiving 
ticagrelor, although this adverse event resulted in ,1% 
discontinuation of the drug. From the DISPERSE-2 study, 
it appears that dyspnea is a dose-related side effect of 
ticagrelor; however, it has not been associated with vascular 
congestion, congestive heart failure, or bronchospasm. The 
etiology of the dyspnea remains unknown, although there 
is speculation that it may be the result of altered adenosine 
metabolism.50
Other notable adverse events with ticagrelor in PLATO 
trial included an increase in the level of serum uric acid 
and serum creatinine. Both of these levels returned to 
baseline at the end of the trial after the study drug was 
discontinued.
Because ticagrelor was given on a twice-daily dosing 
schedule, there has been a concern about patient compli-
ance. If a dose is missed, the patient may be at increased risk 
for stent thrombosis. Upon inspection of the data from the 
ONSET/OFFSET trial, it appears that patients who miss a 
single dose of ticagrelor will have a level of platelet inhibi-
tion comparable with clopidogrel. No statistical difference 
in platelet inhibition, as measured by IPA, was noted until 
both drugs had been stopped for 72 hours.
Conclusion
The mortality benefit of ticagrelor is unique among con-
temporary ACS trials of antiplatelet agents and may be the 
result of a wider separation of antithrombotic effects from 
the bleeding risk when compared with the currently avail-
able thienopyridines.22 Another possible explanation for 
Table 4 Nonbleeding-related adverse events in PLATO trial
Event Ticagrelor Clopidogrel Hazard ratio P value
Dyspnea, any 1270/9235 (13.8) 721/9186 (7.8) 1.84 (1.68–2.02) ,0.001
Dyspnea requiring discontinuation  
of study drug
79/9235 (0.9) 13/9186 (0.1) 6.12 (3.41–11.01) ,0.001
Bradycardia 409/9235 (4.4) 372/9186 (4.0) – 0.21
Syncope 100/9235 (1.1) 76/9186 (0.8) – 0.08
Heart block 67/9235 (0.7) 66/9186 (0.7) – 1.00
Ventricular pauses (first week of study) $3 s 
on Holter monitoring
84/1451 (5.8) 51/1415 (3.6) – 0.01
Ventricular pauses (first week of study) $5 s 
on Holter monitoring
29/1451 (2.0) 17/1415 (1.2) – 0.10
ventricular pauses (at 30 d) $3 s 
on Holter monitoring
21/985 (2.1) 17/1006 (1.7) – 0.52
ventricular pauses (at 30 d) $5 s  
on Holter monitoring
8/985 (0.8) 6/1006 (0.6) – 0.60Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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mortality benefit could be the reported “off-target” effects; 
the P2Y12 receptor exists not only on the platelet surface 
but also in vascular smooth muscle. It is felt that the short 
half-life of the active metabolite of clopidogrel does not allow 
the systemic interaction with the nonplatelet P2Y12 recep-
tor, whereas ticagrelor is systemically available. This could 
conceivably have an effect on the vascular tone and risk of 
thrombosis in tissues by inhibiting the ADP receptor locally. 
Other explanations for the survival benefit seen in the PLATO 
trial include a modulation of the metabolism of adenosine 
or a reduction in the erythrocyte uptake of adenosine.51 Of 
note, in the PLATO trial, all-cause mortality and death due 
to vascular disease were secondary outcomes, and although 
the trial was not powered to assess these secondary outcomes, 
appropriate hierarchical statistical methods allow this analy-
sis to be considered a clinically relevant finding.52
When inspecting the Kaplan–Meier efficacy outcome 
curves of PLATO, it is apparent that the advantage of ticagre-
lor is not immediate and it begins to manifest by 30 days and 
persists over time as the curves continue to separate. Thus, the 
criticism about an inadequate loading dose of clopidogrel53 
becomes less relevant in the longer term, particularly as com-
parison of the outcomes during the initial course of therapy do 
not appear to differ. This contrasts with the results of the TRI-
TON (Trial to Assess Improvement in Therapeutic Outcomes 
by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis 
in Myocardial Infarction [TRITON–TIMI 38]) study,18,19 where 
distinction in these curves between prasugrel and clopidogrel 
was seen within the first few days of therapy.
Despite the advantages observed with ticagrelor, addi-
tional questions do remain. There were 33 subgroups that were 
prespecified and evaluated in PLATO trial and 3 revealed sig-
nificant heterogeneity. A lack of a clear advantage of ticagrelor 
over clopidogrel in North America was found which may 
be spurious54 due to the relatively small number of patients 
enrolled from this region (,10% of total). In FDA briefing 
documents, the drug sponsor suggested that the discrepancy 
between North America and other sites in the PLATO trial 
could be the result of the higher aspirin dosage (the dose used 
in America was typically 325 mg vs 75 or 100 mg outside of 
the United States).55 Unfortunately the FDA reviewers had 
many issues with this analysis, and it was concluded that 
this disparity may not account for the findings. Men who 
weighed ,80 kg and women weighed ,71 kg were found 
not to benefit from ticagrelor compared with clopidogrel. In 
addition, patients who were not taking lipid-lowering drugs on 
enrollment in the study did not seem to benefit. The presence 
of heterogeneity when comparing a large number of subgroups 
needs to be interpreted with caution;56 however, further 
studies are warranted. Additionally, it is unfortunate that no 
long-term follow-up after 12 months, as in a registry, was 
attempted. This must be considered an opportunity lost.
In conclusion, ticagrelor represents advancement over 
currently available oral antiplatelet agents. Its advantages 
include rapid onset of action, a lack of need for metabolic 
conversion, an acceptable safety profile, and documented 
effectiveness in reducing cardiovascular events and mortality 
in the setting of ACS.
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